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REACTION DEVELOPMENT AND MECHANISTIC INVESTIGATION OF RHODIUM–
CATALYZED PYRIDINE SYNTHESIS VIA C–H ACTIVATION 
 
 Described herein are two complementary rhodium–catalyzed methods for the synthesis of 
substituted pyridines from unsaturated oxime derivatives and alkenes.  In the first, formal [4+2] 
cycloaddition of O–pivaloyl α,β–unsaturated oxime esters and activated terminal alkenes was 
discovered to proceed in high yields and with excellent selectivity for 6–substituted pyridine 
products.   Mechanistic experiments were found to be consistent with a reversible C–H activation 
step and a C–N bond forming, N–O bond cleaving process en route to pyridine formation.  
Rhodium–catalyzed coupling using unactivated alkene substrates was shown to present 
important information regarding the influence of the alkene component on product distribution.  
In a second method, access to 5–substituted pyridine derivatives was achieved by 
decarboxylative annulation of α,β–unsaturated oxime esters and β–substituted acrylic acid 
derivatives.  In this case, carboxylic acids were found to serve as traceless activating groups for 
selective alkene incorporation.  A wealth of mechanistic insight was gained by identification of 









I would like to sincerely thank Professor Tomislav Rovis for his guidance during my 
graduate career.  Tom, your critical and incredibly insightful perception of chemistry along with 
your patience and enthusiasm as a mentor create a motivating environment for your students to 
reach their full potential as scientists.  Thank you for giving me freedom to tackle problems my 
own way, for providing direction when I needed help finding my footing, and for always being 
on my team.  
 It has been a true privilege to work with all of the talented and hard–working individuals 
in the Rovis group, past and present.  Thank you all for helpful discussions and for your 
friendship.  I would especially like to thank Stephen Lathrop, Derek Dalton and Kevin Oberg for 
bringing me up to speed in the beginning and their advice throughout the years.  Todd and Oz, it 
was a pleasure to navigate graduate school together with you two.  Darrin, thank you for 
reminding me to not take things too seriously.  Thank you Nick, for your consistent support and 
comic relief.  Tiffany, thank you for sharing your intuition and opinions about chemistry and for 
keeping me entertained.  Clairebear, I cannot explain how grateful I am to have met you.  Thank 
you for being by my side during this tumultuous experience and for carrying me through it when 
I was unable do it alone.    
Finally, I would like to thank my family for their unconditional love and support during 
these and all of my years.  You all keep me grounded and help me remember what is really 
important in life.  Thank you Daddy, for keeping me calm and rational; Mamabear, for always 
lifting me up; Tommy, for giving me perspective; Jason, for truly understanding me; and 
Melissa, for reminding me to be myself.  None of this would have been possible without you.  
! iv 
TABLE OF CONTENTS 
 
CHAPTER ONE: Rhodium(III)–Catalyzed Coupling of α,β–Unsaturated Oxime Esters and 
Alkenes: Selective Synthesis of 6–Substituted Pyridines .......................................................... 1 
1.1 Introduction .......................................................................................................................... 1 
 1.1.1 Nitrogen Heterocycles in Medicinal Chemistry ......................................................... 1 
 1.1.2 Directed Transition Metal–Catalyzed C–H Activation ............................................... 2 
 1.1.3 Pyridine Synthesis by Transition Metal–Catalyzed Formal [4+2] Cycloaddition ...... 4 
 1.1.4 Rhodium–Catalyzed Coupling of 1–Azadiene Derivatives and Alkynes ................... 5 
 1.1.5 Nitrogen–Directed C–H Functionalization with Alkenes ........................................... 8 
1.2 Results .................................................................................................................................. 9 
 1.2.1 Reaction Optimization ................................................................................................ 9 
 1.2.2 α,β–Unsaturated Oxime Ester Scope .......................................................................... 14 
 1.2.3 Activated Alkene Scope .............................................................................................. 17 
 1.2.4 Mechanistic Studies .................................................................................................... 22 
 1.2.5 Discussion of Product Selectivity ............................................................................... 27 
 1.2.6 Unexpected Selectivity with Secondary Alkyl Alkene Substrates ............................. 29 
1.3 Conclusion ........................................................................................................................... 31 
1.4 References ............................................................................................................................ 33 
CHAPTER TWO: Rhodium(III)–Catalyzed Decarboxylative Coupling of α,β–Unsaturated 
Oxime Esters and Acrylic Acids: Selective Synthesis of 5–Substituted Pyridines ................... 40 
2.1 Introduction .......................................................................................................................... 40 
 2.1.1 Product Selectivity in Synthetic Methodology ........................................................... 40 
! v 
 2.1.2 Removable Directing Groups in Transition Metal–Catalyzed C–H Functionalization 
 .............................................................................................................................................. 41 
 2.1.3 Rhodium–Catalyzed Decarboxylative Coupling with β–Substituted Acrylic Acids .. 42 
2.2 Results .................................................................................................................................. 44 
 2.2.1 Reaction Optimization ................................................................................................ 44 
 2.2.2 Substrate Scope ........................................................................................................... 51 
 2.2.3 Mechanistic Studies .................................................................................................... 54 
2.3 Conclusion ........................................................................................................................... 63 
2.4 References ............................................................................................................................ 65 
Appendix One ............................................................................................................................ 69 





Rhodium(III)–Catalyzed Coupling of α,β–Unsaturated Oxime Esters and Alkenes: 
Selective Synthesis of 6–Substituted Pyridines 
 
1.1 Introduction 
1.1.1 Nitrogen Heterocycles in Medicinal Chemistry 
 Nitrogen heterocycles are incredibly important scaffolds in medicinal chemistry.  A 
recent study found 59% of United States FDA approved pharmaceutical drugs,1 including many 
of the most lucrative (Figure 1.1),2 contain a nitrogen heterocycle (N–heterocycle).  In a general 
sense, the prevalence of these scaffolds may be attributed to advantages associated with both the 
nitrogen atom and the cyclic structure (Figure 1.2).  Specifically, nitrogen polarizes the molecule 
and provides a lone pair for hydrogen bonding: two favorable properties in terms of aqueous 
solubility.  As a result, an N–heterocyclic pharmaceutical drug likely exhibits better 
bioavailability than its carbocyclic counterpart.3 On the other hand, the cyclic structure of an N–



















































Figure 1.1 Top N-heterocyclic pharmaceutical drugs by retail sales in 2012.
 2 
corresponding acyclic framework.  
This difference is especially significant 
as it relates to binding of a 
pharmaceutical drug to its biological target, an interaction that carries a large entropic cost due to 
conformational constraints in both components.3a  For an N–heterocyclic drug, the 
conformational degrees of freedom lost upon binding are fewer compared to the acyclic analog, 
resulting in a more entropically favorable interaction.3b 
 
1.1.2 Directed Transition Metal–Catalyzed C–H Activation 
Transition metal–catalyzed C–H bond activation represents a particularly powerful 
approach to constructing complex molecules from simple starting materials.4  By the generally 
accepted definition,5 the process is characterized by direct interaction of a transition metal 
catalyst and a carbon–hydrogen bond, most often resulting in formation of a carbon–metal bond 
(Scheme 1.1a).  In this way, simple starting materials (C–H) are converted to reactive 
intermediates (C–M) that may undergo a variety of transformations to afford value–added 
products (C–Y).  This reactivity, herein referred to as C–H functionalization, offers an attractive 
alternative to cross coupling strategies (Scheme 1.1b) by circumventing the need for activated 
substrates (C–X). 
 Carbon–hydrogen bonds are ubiquitous in organic compounds.  Therefore, a significant 
challenge in transition metal–catalyzed C–H functionalization is site selectivity.  Steric 
repulsion, hybridization of the carbon atom, and acidity of the C–H bond are all factors that may 
N versus
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 3 
contribute variable levels of 
selectivity in the C–H 
activation step.6  Rather, one of 
the most effective ways to 
ensure selectivity in a C–H 
functionalization reaction is 
through the use of a directing group (DG, Scheme 1.2).7  In this case, a coordinating group 
within the substrate engages the transition metal catalyst to bring a particular C–H bond in 
proximity to the metal center.  As a result, directed C–H functionalization reactions typically 
exhibit predictable and reliable site selectivity.  Common directing groups for transition metal–
catalyzed C–H activation are given in Scheme 1.2. 
 In addition to imparting selectivity during the C–H activation step, a directing group may 
be incorporated to afford a cyclic product: a popular concept in N–heterocycle synthesis.8 
Nitrogen–containing substrates often serve as 4–atom components with the generic structure 
illustrated in Scheme 1.3.  Here, nitrogen–directed C–H activation affords a 5–membered aza–
metalacycle that may incorporate a 1– or 2–carbon component, ultimately resulting in annulation 
by C–C and C–N bond formation.  These formal cycloaddition reactions are powerful strategies 
for N–heterocycle synthesis, as multiple bonds of the cyclic core are generated in a single step.  
A variety of N–heterocyclic scaffolds have been accessed by transition metal–catalyzed formal 
cycloaddition including phthalimides,9 isoindolones,10 isoquinolones,11 dihydroisoquinolones,12 










































1.1.3 Pyridine Synthesis by Transition Metal–Catalyzed Formal [4+2] Cycloaddition 
 Substituted pyridines are an especially significant class of nitrogen heterocycles (Figure 
1.3).  A recent analysis of the ring systems encountered in all FDA approved pharmaceutical 
drugs determined the pyridine ring to be the most prevalent.15  Indeed, the development of 
methods to access pyridine derivatives is a topic of continued interest for synthetic chemists, 
illustrated by the wealth of elegant examples that have recently contributed to this field.16,17 
Using the general concept 
shown in Scheme 1.3, we can devise a 
route to pyridine products from 1–
azadiene derivatives and alkynes (Scheme 1.4).  Several reports have taken advantage of such 
formal [4+2] cycloaddition approaches for the synthesis of substituted pyridines.18  Transition 
metal catalysts in these examples are typically rhodium–based.19  Pyridine formation may be 





























































Figure 1.3 Selected biologically active pyridines.
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relevant to the 
mechanism of the 
C–H activation 
step (Scheme 
1.5).20  In 
general, C–H activation is proposed to proceed by oxidative addition to the C–H bond in 
rhodium(I)–catalyzed methods  (Scheme 1.5a), while rhodium(III) catalysts are thought to 
operate by base–assisted deprotonation or concerted metalation deprotonation21 (Scheme 1.5b, 
shown for a carboxylate base).  
 
1.1.4 Rhodium–Catalyzed Coupling of 1–Azadiene Derivatives and Alkynes  
In their longstanding contribution to the field of C–H functionalization,7b Bergman and 
Ellman have shown N–alkyl imines provide suitable directing groups for rhodium–catalyzed C–
H bond activation.22  They applied this insight to the synthesis of substituted pyridines by Rh(I)–
catalyzed annulation of α,β–unsaturated N–benzyl imines (N–benzyl 1–azadienes, 1) and alkynes 
(2, eq 1, Scheme 1.6).23  In this study, the authors found the stoichiometric reaction of imine 1a 
leads to formation of rhodium hydride complex 3a (eq 2), providing evidence for C–H activation 
by an oxidative addition mechanism.  They propose pyridine formation proceeds by imine–
directed C–H activation to access aza–metalacycle 3, followed by migratory insertion of the 
alkyne substrate (2) and reductive elimination to afford azatriene intermediate 4.  Subsequent 
6π–electrocyclization provides an N–benzyl dihydropyridine derivative 5 that is isolable by 
chromatography.  Rather, oxidation and removal of the benzyl group may be conducted in the 


















Scheme 1.5 Mechanisms proposed for Rh-catalyzed C−H activation.
 6 
As illustrated in Scheme 1.4, pyridine formation by formal [4+2] cycloaddition of 1–
azadienes and alkynes requires overall loss of H–Z.  Compared to an N–alkyl 1–azadiene, this 
process is simplified in the case of an unsubstituted (N–H) 1–azadiene.  Indeed, Jun and 
coworkers demonstrated Rh(III)–catalyzed annulation of α,β–unsaturated N–H imine derivatives 
and alkynes accesses pyridine products (6) directly in the presence of a copper(II) acetate oxidant 
(Cu(OAc)2, eq 3).24  In this method, unstable N–H imine substrates are generated in situ by 
condensation of the corresponding ketones (7) and ammonium acetate (NH4OAc). 
 When the N–substituent (Z in Scheme 1.4) of a 1–azadiene is a leaving group, the 
nitrogen directing group can provide an ‘internal’ oxidant.25  The most commonly encountered 
oxidizing directing groups in pyridine synthesis by formal [4+2] cycloaddition are oxime 
derivatives (Z = OR).26  In their seminal report, Cheng and coworkers demonstrated the Rh(I)–
catalyzed intermolecular27 coupling of α,β–unsaturated oximes (8) and alkynes (eq 4).28  In this 
case, loss of H–Z (Scheme 1.4) is accomplished by elimination of water, obviating the need for 
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catalysis (eq 5).29  In both 
examples, reactions of 
unsymmetrical alkynes afford 
regioisomeric mixtures with little 
selectivity (shown for the Rh(III)–
catalyzed reaction, conditions A, 
eq 7), presumably the reason 
nearly all alkyne substrates are 
symmetrical. 
Hyster and Rovis explored 
a ligand modification strategy for 
enhancing selectivity in Rh(III)–
catalyzed coupling of α,β–
unsaturated oximes (8) and unsymmetrical alkynes (9, eq 6).30  They identified a bulky di–tert–
butylcyclopentadienyl ligand (Cpt) that results in substantial improvements in selectivity and 
reactivity (eq 7).  Furthermore, mechanistic studies support a concerted metalation deprotonation 
pathway for C–H activation in this case.  
 Terminal alkyne substrates are often problematic in transition metal–catalyzed reactions, 
including the examples discussed thus far, since they are susceptible to a variety of side 
reactions.31  Bergman and Ellman addressed this issue in their report of Rh(I)–catalyzed formal 
[4+2] cycloaddition of α,β–unsaturated oximes and terminal alkynes (12, eq 8).32  In the presence 
of a phosphite ligand (P(OiPr)3), reactions afford mixtures of pyridine isomers 13 and 14 with 
selectivities that range from 1:1.6 to <1:20 13/14 (eq 8). 
6
26 examples






[RhCp*Cl2]2 (2.5 mol %)
CsOPiv (30 mol %)
6
19 examples







MeOH, 150 °C, MW7
NH4OAc (2 equiv)



































1.1.5 Nitrogen–Directed C–H Functionalization with Alkenes 
 One possible alternative to the 
alkyne component in rhodium–
catalyzed coupling with 1–azadienes 
is use of an alkene substrate in combination with a stoichiometric oxidant (Scheme 1.7).  The 
numerous reports of alkene incorporation by rhodium–catalyzed, nitrogen–directed C–H 
functionalization reactions support the feasibility of this approach to pyridine synthesis.33  In one 
relevant example, Bergman and Ellman showed Rh(I)–catalyzed coupling of α,β–unsaturated N–
benzyl imines (1) and terminal alkenes (15) affords β–alkylated products 16, isolated after 
B: [RhCptCl2]2 (2.5 mol %)
    K2CO3 (2 equiv)

















A: [RhCp*Cl2]2 (2.5 mol %)
    CsOPiv (30 mol %)


























1 : 1 −  10 : 1 10/11
45 − 95% yield
10 11
+
A → 1.5 : 1 10aa/11aa, 45% yield
B  → 5.0 : 1 10aa/11aa, 89% yield
NRn
[Rh(coe)2Cl]2 (5 mol %)
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− H−Z   − H2
 9 
hydrolysis upon purification by chromatography (eq 9).34  The same authors demonstrated oxime 
ethers (18) are effective directing groups for Rh(III)–catalyzed C–H functionalization with 
alkenes (eq 10).35  The reaction is conducted in the presence of an oxidant (Cu(OAc)2) to provide 
unsaturated products 19.  Notably, in both cases, alkene substrates incorporate selectively to 
afford only linear products (eqs 9 and 10). 
 
1.2 Results36 
1.2.1 Reaction Optimization  
Limitations associated with pyridine synthesis by formal [4+2] cycloaddition of α,β–
unsaturated oximes and alkynes, as well as the established reactivity of alkenes in C–H 
functionalization reactions, prompted our investigation of rhodium–catalyzed annulation of α,β–
unsaturated oxime derivatives and alkenes.  We began with O–methyl α,β–unsaturated oxime 
ether 20 (eq 11), an alkenyl analog of the aryl oxime ether substrates employed by Bergman and 
Ellman (18, eq 10).  Using [RhCp*Cl2]237 (Cp* = pentamethylcyclopentadienyl) as the catalyst, 
16
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5 − >20 : 1 (E)/(Z)
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the desired reaction of 20 does not proceed under a variety of conditions (eq 11).  We turned our 
attention to O–acetyl oxime ester 21 (Ac = C(O)Me, eq 12), since oxime esters are also known to 
be effective directing groups for rhodium–catalyzed C–H activation.14b,g,i  Reaction of 21 and 
ethyl acrylate (15a) in 2,2,2–trifluoroethanol (TFE) with 2.1 equivalents silver(I) acetate 
(AgOAc) as the external oxidant affords no pyridine products 13aa or 14aa; rather, isoxazole 23 
is observed (eq 12).  Formation of 23 may proceed by ester solvolysis to release unsubstituted 
derivative 22 (eq 12), followed by intramolecular cyclization.  The reaction of 22 also affords 
isoxazole 23 in 35% yield, consistent with this proposed pathway.   
We hypothesized the bulky tert–butyl substitutent of O–pivaloyl oxime ester 24a (Piv = 
C(O)tBu, eq 13) would suppress isoxazole formation by preventing decomposition to 
unsubstituted oxime 22.  We were delighted to find desired annulation of 24a and ethyl acrylate 
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of 6–substituted pyridine 13aa and no 5–substituted isomer 14aa is observed.  Partial 
transesterification of 13aa with the solvent also occurs, leading to an approximately 4:1 mixture 
of ethyl and trifluoroethyl esters (eq 13). 
The interaction of 
pyridine 13aa and TFE 
prompted a screen of 
reaction solvents (Table 
1.1).  Little or no product 
formation occurs in a range 
of media including nonpolar 
(entry 2), polar aprotic 
(entries 3–7), and polar 
protic (entries 8–10) 
systems.  Only use of 
perfluorinated alcohol 
solvents TFE and 
1,1,1,3,3,3–hexafluoroisopropanol (HFIP) results in observable amounts of pyridine formation 
(entries 1 and 11).  We speculated the substantial difference in reactivity between alcohol 
solvents ethanol (EtOH) and isopropanol (iPrOH) compared to their perfluorinated analogs TFE 
and HFIP could be attributed to the difference in acidity.  Specifically, the pKa’s of TFE and 
HFIP are 23.5 and 18.2 in DMSO, respectively, and those of EtOH and iPrOH are 29.8 and 30.3 
in DMSO, respectively.38  With this in mind, we evaluated more acidic solvent systems.  Indeed, 
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aConditions: 1.2 equiv 15a, 0.15 M. bDetermined by 1H NMR.
c~4:1 mixture of Et and CH2CF3 esters.
Table 1.1. Optimization of the reaction solvent.a
 12 
Employing AcOH as a 
mixture with 1,2–
dichloroethane (DCE) 
lessens decomposition of 
the oxime substrate (24a), 
and pyridine 13aa forms in 
45% yield using a 2:1 
DCE/AcOH solvent system 
(entry 15).  Increasing 
reaction concentration favors pyridine formation (Table 1.2), accessing 13aa in 65% yield at the 
optimal concentration of 0.3 molar (M, entry 3).  Rh(III)–catalyzed coupling of 24a and 15a does 
not proceed at room temperature (entry 5) and decreasing reaction temperature to 60 ºC results in 
lower yield (entry 6).  Substrate decomposition occurs at elevated temperature, leading to 50% 
yield of 13aa (entry 7).  
Previous work in the Rovis group showed the substituents of a cyclopentadienyl ligand 
can have significant effects in Rh(III)–catalyzed annulation of unsaturated oximes and alkynes.30   
With this in mind, we examined the reaction of 24a and alkene substrate 15a in the presence of 
various [RhCpxCl2]2 complexes (Table 1.3).  Use of electron–deficient catalysts containing CpCF3 
or CpE ligands leads to significantly lower reactivity (entries 2 and 3).  Interestingly, 6–
substituted pyridine 13aa still forms with >20:1 selectivity when bulky tert–butyl–substituted 
[RhCptCl2]2 is employed, but in slightly lower yield (entry 4).   
Finally, we evaluated potential oxidizing reagents (Table 1.3).  It is worth noting, in 
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aConditions: 1.2 equiv 15a. bDetermined by 1H NMR.
Table 1.2. Optimization of concentration and temperature.a
 13 
rhodium acetate complex by halide abstraction from [RhCp*Cl2]2.39  Therefore, screening of 
other external oxidants was conducted using preformed rhodium acetate catalyst RhCp*(OAc)2.  
Copper(II) acetate (Cu(OAc)2) is a common oxidant for rhodium–catalyzed N–heterocycle 
synthesis via C–H activation,11g,j,13a,c however, reaction of 24a and 15a with 2.1 equivalents 
Cu(OAc)2 affords no desired product (entry 7).  Use of ceric ammonium nitrate (CAN) results in 
complete decomposition of the oxime substrate (entry 8).  Pyridine formation proceeds in the 
presence of organic oxidants anthraquinone (entry 10), 2,2,6,6–tetramethylpiperidine 1–oxyl 
(TEMPO, entry 11), and N–methylmorpholine N–oxide (NMO, entry 12).  However, yields of 





DCE/AcOH (2:1), 85 °C
>20 : 1 regioselectivity24a
RhCpxX2 (5 mol % in Rh)






















































aConditions: 1.2 equiv 15a, 0.3 M. bDetermined by 1H NMR. c5 mol % [RhCp*Cl2]2.



























1.2.2 α,β–Unsaturated Oxime Ester Scope 
We explored the scope 
of the reaction using AgOAc as 
the external oxidant, beginning 
with the oxime substrate (24, 
Chart 1.1).  O–Pivaloyl α,β–
unsaturated oxime esters are 
easily accessed from the 
corresponding ketones by 
condensation with 
hydroxylamine hydrochloride 
and subsequent acylation with pivaloyl chloride (see Appendix 1.3).  Reactions of β–aryl and β–
alkyl substrates 24b and 24c result in little product formation.  We wondered if the diminished 
reactivity compared to 24a could be due to lack of α–substitution, so α–methyl derivatives 24d 
and 24e were prepared.  However, coupling with ethyl acrylate (15a) proceeds with similarly low 
conversion in both cases.  We were delighted to find the reaction of β–H α,β–unsaturated oxime 
ester 24f affords pyridine 13fa with >20:1 selectivity and in 90% isolated yield.  The related 
substrate 24g also undergoes formal [4+2] cycloaddition to provide 13ga in 90% yield.  
At this point in our study, we chose to reevaluate alternative external oxidants using the 
more reactive substrate 24f (Table 1.4).  Similar to the reaction of 24a (Table 1.3), low 
conversion is observed in the presence of anthraquinone or NMO (entries 1 and 2).  Employing 
2.1 equivalents of organic oxidant TEMPO, on the other hand, leads to formation of 13fa in 80% 
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Me
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reactivity (entry 4).  In the case of a Cu(OAc)2 oxidant, 1H NMR data suggests polymerization of 
the alkene substrate occurs, likely precluding pyridine formation (entry 5). 
Several studies have investigated the use of atmospheric oxygen as a terminal oxidant for 
Rh(III)–catalyzed C–H functionalization reactions,40 typically in the presence of catalytic 
copper(II) reagents.13a,33a  Reaction of 24f, 15a, and 20 mol % Cu(OAc)2 under air, however, 
leads to decomposition (entry 6).  Surprisingly, the same reaction without Cu(OAc)2 affords 
pyridine 13fa in 50% yield (entry 7).  Moreover, complete conversion of 24f is observed in the 
reaction conducted under an atmosphere of argon, and pyridine 13fa is isolated in 45% yield 
(entry 8).  These observations are consistent with a pathway in which the N–O bond of 24f acts 
as both the internal and external oxidant for pyridine formation.  With this in mind, other 
potential oxidants containing N–O bonds were examined (25, 26 and 27); however, diminished 
reactivity is observed these cases (entries 9–11). 
CO2Et
13



































aConditions: 1.2 equiv 15a, 0.3 M. bDetermined by 1H NMR.
cReaction vial not flushed with Ar. dIsolated yield.
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Since other oxidizing reagents provided no improvement to the reaction of 24f and 15a, 
we continued our investigation of the reaction scope using AgOAc as the oxidant.  Results of 
Rh(III)–catalyzed coupling of various O–pivaloyl α,β–unsaturated oxime esters 24 and ethyl 
acrylate (15a) are provided in Chart 1.2.  Importantly, 6–substituted products are formed with 
>20:1 selectivity in all cases.  α–Alkyl and α–aryl substrates undergo the desired annulation to 
access 2,3,6–trisubstituted pyridines 13f,g and 13i in excellent yields.  The primary alkyl 
chloride functionality in 24j is tolerated in the presence of the Ag(I) reagent, and the slightly 
larger butyl substituent of oxime 24k does not diminish reactivity.  Pyridine formation also 
proceeds with vinyl oxime substrate 24l to afford disubstituted pyridine 13la, but in lower yield.  
Use of electron deficient substrate 24m results in low conversion (eq 14), while electron rich 
substrate 24n undergoes cyclization to isoxazole 28 (eq 15).  Reaction of aldoxime ester 24o 
does not provide the pyridine product; rather, elimination of PivOH occurs under the reaction 



















aConditions: 1.2 equiv 15a, 0.3 M, 14 h.
Me









[RhCp*Cl2]2 (2.5 mol %)
AgOAc (2.1 equiv)
DCE/AcOH (2:1), 85 °C
>20 : 1 regioselectivity15a24 13
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1.2.3 Activated Alkene Scope 
A variety of electron deficient terminal alkenes undergo Rh(III)–catalyzed formal [4+2] 
cycloaddition with α,β–unsaturated oxime ester 24f (Chart 1.3).  Reactions of benzyl and phenyl 
acrylate (15b and 15c), N,N–Dimethylacrylamide (15d) and methyl vinyl ketone (15e) all 
provide 6–substituted pyridine products with >20:1 selectivity and in good yield.  It is worth 
mentioning that an observed byproduct in the case of N,N–dimethylacrylamide (15d) is alkyl 
acetate 30 (eq 17), a compound that inseparable from the pyridine product 13fd by 
chromatography.  Fortunately, use of excess oxime substrate 24f suppresses formation of 30, 
allowing isolation of 13fd in 81% yield.  Alkene decomposition competes with pyridine 
formation in the case of acrolein (15f), and pyridine 13ff forms with a maximum yield of 35% in 
the presence of 3 equivalents 15f.  Interestingly, Rh(III)–catalyzed annulation does not proceed 
with acrylonitrile (15g).  To test for inhibition of pyridine formation by the nitrile group, perhaps 
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Me Me[RhCp*Cl2]2 (2.5 mol %)
AgOAc (2.1 equiv)
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with this hypothesis, 
addition of 1.2 equivalents 
15g to the standard reaction 
of 24f and 15a leads to a 
significantly decreased 
yield of 13fa (32% versus 
92% yield, Chart 1.2). 
Rh(III)–catalyzed 
coupling of oxime 24f and 
styrene (15h) or 2–vinyl 





























Chart 1.3. Electron deficient alkene scope.a
aConditions: 1.2 equiv 15a, 0.3 M, 14 h. b1.2 equiv 24f. c75 °C.









[RhCp*Cl2]2 (2.5 mol %)
AgOAc (2.1 equiv)
DCE/AcOH (2:1), 85 °C
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    15h, R = H → 1.3 : 1  13fh/31h
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complete conversion and >20:1 selectivity for 6–substituted isomers (eq 19).  However, 2–aryl 
pyridine products (13) are capable substrates for directed C–H activation;41 therefore, 13fh and 
13fi are generated as mixtures with olefinated products 31h and 31i.  We investigated strategies 
for suppressing the second C–H activation event in the reaction of 15h (Table 1.5).  Less 
olefinated product 31i is observed at lower concentrations, but reactivity is also diminished 
(entries 2 and 3).  Similarly, slow addition of 15h disfavors olefination but pyridine 13fh forms 
in lower yield (entry 4).  Fortunately, pyridine 13kh is the only observed product in the reaction 
of butyl–substituted oxime 24k, isolated in 61% yield (entry 5). 
We explored the scope of aryl alkene substrates using oxime 27k (Chart 1.4).  The 
desired annulation of 2–, 3–, and 4–vinyl anisole (15i–k) generates 6–aryl pyridine products 
selectively in good yields.  The fluoride, chloride, and bromide substituents of alkenes 15l–n are 
tolerated under the reaction conditions.  Electron deficient 3–(trifluoromethyl)styrene (15o) 
participates to afford 13ko in 56% yield, while little or no conversion is observed in reactions of 
2– and 4–vinyl pyridine (15p and 15q). 
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We investigated the incorporation of internal alkene substrates, beginning with methyl 
crotonate ((E)–32a).  Reaction of 24f and (E)–32a under the optimized conditions affords 6–
carboxymethyl pyridine 33fa as the only observed product in 32% yield (eq 20).  A control 
experiment was performed to probe potential product inhibition (eq 21), perhaps by coordination 
of the slightly more electron rich pyridine 33fa to rhodium.  In fact, reaction of 24f and (E)–32b 
affords 33fb in 35% yield in the presence of 1 equivalent pyridine 33fa, suggesting product 





















aConditions: 1.05 equiv 15, 0.3 M, 14 h.
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Reactions of oxime 24f and various internal alkene substrates 32 were examined (Chart 
1.5).  Interestingly, (E)– and (Z)–isomers of ethyl crotonate (32b) participate with similar 
reactivity, affording pyridine 33fb in 51% and 47% yield, respectively.  Methyl fumarate (32c) is 
a particularly reactive substrate, and 33fc forms in 71% yield.  Acetyl methyl acrylate (32d) 
incorporates with a surprisingly high level of selectivity for 6–carboxymethyl pyridine 33fd.  
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Chart 1.5. Internal alkene scope.a






32f diminishes reactivity.  Both (E)– and (Z)–methyl cinnamate (32g) are unreactive under these 
conditions. 
 
1.2.4 Mechanistic Studies 
Several observations contributed to our current understanding of the reaction mechanism.  
The control reaction of 24f and 15a without rhodium catalyst results in no conversion to the 
pyridine product (eq 22), providing evidence against annulation by thermal [4+2] 
cycloaddition.42  Prior observations indicate coupling of 24f and 15a proceeds in the absence of 
added oxidant when the catalyst is acetate complex RhCp*(OAc)2 (Table 1.4 and eq 23).  On the 
other hand, use of chloride complex [RhCp*Cl2]2 in the analogous reaction completely 
suppresses product formation (eq 23).  That reactivity hinges upon the presence of a carboxylate 
is consistent with C–H activation by a concerted metalation deprotonation mechanism.21a 
Isotope experiments provided further insight regarding the mechanism of pyridine 
formation.  Reaction of 24f and 15a using acetic acid–d (AcOD) results in significant deuterium 
incorporation at the β–position in 24f–d after 60% conversion (eq 24), an observation consistent 
with reversible C–H activation at this site.  In the same reaction, near complete deuteration of the 
2–methyl substituent in 
pyridine 13fa–dn occurs, 
implicating reversible 
deprotonation at this 
position at some point in 
the reaction.  The control 








CO2EtDCE/AcOH (2:1), 85 °C
X = OAc → 45% yield






















and 1 equivalent 13fa leads to no deuterium incorporation in 13fa (eq 25), ruling out deuteration 
by background deprotonation of the pyridine product.  Instead, deprotonation likely takes place 
en route to the pyridine product.  Since no deuterium incorporation at the corresponding site in 
oxime 24f–d is observed, the deprotonation step is likely preceded by the first irreversible step of 
the reaction mechanism. 
Based on these and forthcoming observations, we propose Rh(III)–catalyzed annulation 
of α,β–unsaturated oxime ester 24f and alkene 15a proceeds by the mechanism depicted in 
Figure 1.4.  Silver(I)–promoted ligand exchange generates active rhodium acetate catalyst I.  
Carboxylate dissociation provides an available site for coordination by 24f to form intermediate 
II.  Reversible C–H activation by carboxylate–assisted concerted metalation deprotonation at the 
β–position of 24f affords rhodacycle III.  Alkene coordination and migratory insertion to the Rh–
C bond provides cationic intermediate V.  Deprotonation of the 2–methyl group accesses neutral 
complex VI. 
Two distinct pathways to pyridine 13fa from 7–membered rhodacycle VI are feasible.  In 
the first, β–hydride elimination affords azatriene intermediate VIII’ (Scheme 1.8).  Subsequent 








[RhCp*Cl2]2 (2.5 mol %)
AgOAc (2.1 equiv)















































formation occurred by this mechanism, then reaction of a cis–fused alkene like 1,2–
dihydronaphthalene (32h) should not proceed, since the trans relationship between rhodium and 
hydride substituents in intermediate VIa (eq 26) would preclude the cis–coplanar geometry 
required for elimination.6  In fact, Rh(III)–catalyzed coupling of 24k and 32h affords pyridine 
33kh in 32% yield (eq 26), implying a different pathway. 
Glorius and coworkers’ report of C–H functionalization in hydroxamic acid derivatives 
(35, Scheme 1.9)12g provides insight regarding the mechanism of pyridine formation from 
intermediate VI in Figure 1.4.  During the course of their study, the authors discovered the 






























































































Figure 1.4. Proposed mechanism for formation of pyridine 13fa.
 25 
hydroxamic acid O–substituent (eq 27).  Specifically, O–methyl ether 35a couples with styrene 
(15h) to afford olefinated product 37, presumably via β–hydride elimination from rhodium 
complex 36a (eq 27, right).  On the other hand, the analogous reaction of O–pivaloyl ester 35b 
produces dihydroisoquinolone 38 (eq 27, left).  The authors suggest chelation by the pivalate 
group in intermediate 36b prevents β–hydride elimination, since 36b is a coordinatively 
38
86% yield
[RhCp*Cl2]2 (2.5 mol %)
AgOAc (2.1 equiv)
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saturated complex.6  Instead, an N–O bond cleaving, C–N bond forming event occurs, ultimately 
leading to cyclized product 38.12g 
We propose coordination of the pivalate group in VI generates saturated complex VII 
that undergoes a C–N bond forming, N–O bond cleaving process to provide rhodium amide VIII 
(Figure 1.4).  From VIII, protonolysis of the Rh–N bond with AcOH is possible (Scheme 1.10), 
regenerating active catalyst I and accessing 1,2–dihydropyridine intermediate IX’ that is 
oxidized by the external oxidant to afford pyridine 13fa.  However, experimental observations 
are not fully consistent with the pathway shown in Scheme 1.10.  For one, Ag(I) reagents are not 
common in methods for pyridine synthesis by oxidation of dihydropyridines.44  In fact, oxidative 
aromatization reactions of 1,2–dihydropyridine derivatives analogous to IX’ are often conducted 
using relatively weak oxidants.45  In the present study, on the other hand, examination of several 
oxidizing reagents (Table 1.3) found only AgOAc to be effective for accessing pyridine 13aa, a 
distinction that suggests the role of the oxidant is not aromatization of a 1,2–dihydropyridine 
intermediate (XI’).  Furthermore, reaction 24f, 15a and 100 mol % RhCp*(OAc)2 results in 
formation of 13fa and a rhodium hydride species (eq 28), tentatively assigned as 39 based on 1H 


























R  = Me and tBu


























Scheme 1.10.  Rather, we propose β–hydride elimination from intermediate VIII affords pyridine 
13fa and rhodium hydride complex IX (Figure 1.4).  Reductive elimination of PivOH from IX 
provides a Rh(I) species X that is oxidized by Ag(I) to regenerate active catalyst I.  
 
1.2.5 Discussion of Product Selectivity 
Unactivated terminal alkenes are also reactive substrates for Rh(III)–catalyzed formal 
[4+2] cycloaddition with O–pivaloyl α,β–unsaturated oxime esters.  For example, coupling of 
oxime 24f and 1–octene (15r) proceeds with complete conversion under the optimized 
conditions (eq 29).  However, approximately equal amounts of 6– and 5–substituted products 
13fr and 14fr are observed in this case.  The difference in selectivity between reactions of 
activated terminal alkenes 15a–q (>20:1 13/14, vide supra) and unactivated substrate 15r may be 
explained in terms of the selectivity–determining step of the mechanism proposed in Figure 1.4: 
migratory insertion (IV → V). 
In general, migration insertion of a terminal alkene installs the substituent (R) at either an 
α– or β–position relative to the metal center (Scheme 1.11), processes termed 2,1– and 1,2–
insertion, respectively.6  With respect to the present study, 2,1–insertion from complex IVa leads 
to Va and, ultimately, 6–substituted pyridines 13 (Scheme 1.11a), while 1,2–insertion results in 
rhodacycle Vb and 5–substituted products 14 (Scheme 1.11b).  Electron deficient and aryl 
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1 : 1.3 13fr/14fr
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an explanation for the selective incorporation of these substrates to afford 6–substituted pyridines 
13 (vide supra).  On the other hand, alkyl alkenes often participate by both 2,1– and 1,2–
insertion pathways,6 consistent with formation of a mixture of 13fr and 14fr in the reaction of 1–
octene (15r).   
We can also discuss steric effects on the migratory insertion step using the model 
provided in Scheme 1.11.  If the alkene substituent (R) is large, steric repulsion between the 
substituent and the environment around the metal center presumably favors orientation of the 
alkene as illustrated in IVb (Scheme 1.11b).  Therefore, use of a bulky terminal alkene substrate 
should lead to selective 1,2–insertion and formation of 5–substituted pyridine 14.  Indeed, 
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<1 : 20 13fs/14fs
 29 
yield (eq 30).  By the same logic, modification of the steric environment through the use of a 
cyclopentadienyl ligand with bulky substituents should also favor formation of 5–substituted 
products 14 (Chart 1.6).46  Consistent with this hypothesis, reaction of oxime 24f and 1–octene 
(15r) in the presence of [RhCptCl2]2 affords a mixture of products with 3.3:1 selectivity for 5–
substituted pyridine 14fr.  However, only 20% combined yield is observed in this case.  Use of 
monosubstituted ligand CpiPr leads to similarly low conversion.  Reactivity is recovered in the 
presence of [RhCp*iPrCl2]2, implying pentasubstitution of the cyclopentadienyl ligand is 
important for reactivity.  Additional iso–propyl groups in Cp*iPr3 do not significantly affect the 
reaction of 24f and 15r, resulting in a 1:2.6 mixture of 13fr and 14fr in 40% combined yield.   
 
1.2.6 Unexpected Selectivity with Secondary Alkyl Alkene Substrates 
 It is reasonable to predict, based on the observations in equations 29 and 30, Rh(III)–
catalyzed coupling of oxime 24f and a secondary alkyl alkene will generate a mixture of 
products with a level of selectivity for 5–substituted product 14.  In fact, 6–substituted pyridines 







1 : 1.3 13fr/14fr
20% comb. yield
1 : 3.3 13fr/14fr
15% comb. yield
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Chart 1.6. Investigation of the cyclopentadienyl ligand.a,b
 30 
(Table 1.6).  Perhaps the most striking of these results is the significant difference in selectivity 
between reactions of vinyl cyclopentane (15t, 1.3:1 selectivity) and vinyl cyclohexane (15u, 
7.2:1 selectivity).  The control reaction of 24f and 1.2 equivalents 15t and 15u leads to 
incorporation of both alkene substrates with selectivities that are similar to those observed in the 
standard reaction (eq 31), suggesting a contaminant in either reagent is not responsible for the 
difference. 
 One property that varies among secondary alkyl alkenes 15t–w is conformation.  In this 
respect, cyclohexane is unique, since it exists predominantly in one conformation: the chair form.  
Furthermore, in vinyl cyclohexane (15u), the conformer in which the vinyl substituent occupies 
an equatorial position is favored by 1.5–1.7 kcal/mol compared to the axial isomer.47  As a result, 
vinyl cyclohexane (15u) likely exhibits higher conformational rigidity compared to other 
secondary alkyl alkene substrates.  To probe conformational effects in Rh(III)–catalyzed 
coupling of 24f and alkyl alkenes, tert–butyl–substituted derivatives 15x were prepared (eqs 32 
and 33).  Preference for an equatorial tert–butyl group (favored by 4.7–4.9 kcal/mol in tert–
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Table 1.6. Secondary alkyl alkene scope.a
 31 
the vinyl substituent is equatorial in trans–15x and axial in cis–15x.  Reaction of 24f and trans–
15x favors formation of 6–substituted pyridine trans–13fx with 7.1:1 selectivity (eq 32).  On the 
other hand, reaction of 24f and cis–15x leads to a 3.1:1 mixture of 13fx (4.4:1 cis/trans isomers) 
and cis–14fx.  These results suggest Rh(III)–catalyzed coupling of alkyl alkenes is influenced by 
conformation; however, the reason for this effect is not fully understood at this time. 
 
1.3 Conclusion 
 In conclusion, we developed a synthetic method for accessing substituted pyridines by 
Rh(III)–catalyzed annulation of α,β–unsaturated O–pivaloyl oxime esters and alkenes.  Reactions 












1 : 1.1  R  = Cyp/R  = Cy
R = Cyp → 1.6 : 1 13ft/14ft
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7.1 : 1 13fx/14fx
40% combined yield
3.1 : 1 13fx/14fx
 32 
excellent yields.  Mechanistic studies support pyridine formation by reversible C–H activation, 
selective 2,1–insertion and a C–N bond formating/N–O bond cleaving process.  Both ligand and 
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Rhodium(III)–Catalyzed Decarboxylative Coupling of α,β–Unsaturated Oxime 
Esters and Acrylic Acids: Selective Synthesis of 5–Substituted Pyridines 
 
2.1 Introduction 
2.1.1 Product Selectivity in Synthetic Methodology 
 In any synthetic method, selectivity for the desired product is just as important as 
reactivity.1  If a reaction is complete but multiple products are generated, starting materials 
incorporated into undesired isomers go to waste.  Fortunately, chemical transformations often 
exhibit remarkable sensitivity to the steric and electronic nature of substrates.  In a classic 
example, appropriately activated π–components undergo Diels Alder cycloaddition selectively 
based on favorable orbital interactions,2 providing a reliable route to compounds like 1 (Scheme 
2.1, EDG = electron–donating group, EWG = electron–withdrawing group).  However, a 
synthetic target may require a substitution pattern contrary to what is dictated by inherent 
substrate bias (as in 2) or one involving substrates that lack necessary properties for selectivity, 
for instance, Diels Alder cycloaddition of an unactivated alkene to afford 3 (Ak = alkyl).  If so, 
access to the synthetic target necessitates either an alternate method or a means of encouraging 
selectivity. 
 Synthetic chemists have devised a variety of clever strategies for promoting selectivity in 
otherwise unselective 
transformations.  One 
such strategy is the use 
of a directing group for 
! 41 
site selectivity in transition metal–catalyzed C–H functionalization (Scheme 2.2).3  As an 
illustration, ignoring any steric or electronic influence of the substituent (R), C–H activation of 
benzene derivative 4 presumably affords a mixture of isomeric products 5 (Scheme 2.2a).  In the 
case of substrate 6, on the other hand, coordination of the catalyst by the directing group (DG) 
brings the adjacent C–H bond in proximity to the metal center, resulting in selective C–H 
activation and formation of functionalized product 7 (Scheme 2.2b). 
 
2.1.2 Removable Directing Groups in Transition Metal–Catalyzed C–H Functionalization 
 One potential caveat in directed C–H functionalization reactions is inclusion of directing 
groups within products.  With this in mind, considerable research effort has targeted 
incorporation of synthetically useful directing groups.4  Conversely, several studies have 

























Scheme 2.2. Selectivity in C−H functionalization.
transition
metal catalystH














examples, C–H activation proceeds selectively without requiring directing groups in the 
functionalized products.  
Carboxylic acids are effective directing groups for C–H activation in a variety of 
functionalization reactions (8 → 9, Scheme 2.3).7  Furthermore, several reports have 
demonstrated decarboxylation processes8 that result in carboxylic acid removal from a variety of 
(hetero)aryl substrates (9 → 10).9 Indeed, these two modes of reactivity have been combined for 
selective C–H functionalization reactions in which carboxylic acids serve as removable directing 
groups (8 → 10, Scheme 2.3) for C–H alkenylation,10 arylation11 and etherification.12 
 
2.1.3 Rhodium–Catalyzed Decarboxylative Coupling with β–Substituted Acrylic Acids 
 We envisioned a related decarboxylation strategy for pyridine synthesis by Rh(III)–
catalyzed annulation of O–pivaloyl α,β–unsaturated oxime esters (11) and acrylic acid 
derivatives (14, Scheme 2.4).  Our previous research showed electron deficient terminal alkenes 
(12) incorporate with exquisite selectivity to access 6–substituted pyridines (13, eq 1).13  These 




































































stronger, more polar Rh–C bond in intermediate IIa.14  Likewise, complex Ib should undergo 
migratory insertion to favor installation of the carboxylic acid moiety α to the metal center (thus 
placement of the substituent β) in rhodacycle IIb.  Ideally, subsequent decarboxylation would 
proceed in situ to afford pyridine products directly.15  In this way, Rh(III)–catalyzed coupling of 
α,β–unsaturated oxime esters (11) and acrylic acid derivatives (15) should access 5–substituted 
pyridine products (15, eq 2) selectively,16,17 complementing our prior work in this area.13 
 The reaction of oxime substrate 11a and acrylic acid (16, eq 3) provided inspiration for 
the proposed decarboxylative method for pyridine synthesis.  In the presence of catalytic 
[RhCp*Cl2]2 (Cp* = pentamethylcyclopentadienyl) and 2.1 equivalents silver(I) acetate 
(AgOAc), the expected picolinic acid product 18a is not observed.  Instead, the reaction affords 













[RhCp*Cl2]2 (2.5 mol %)
AgOAc (2.1 equiv)
























































Table 2.1. Initial optimization with acrylic acid (16).a
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solvents and concentrations (Table 2.1) found a 0.3 M solution of 2,2,2–trifluoroethanol (TFE) to 
be optimal for reactivity, providing 17a in 85% yield (entry 4). 
 
2.2 Results18 
2.2.1 Reaction Optimization 
We turned our attention to the synthesis of 5–substituted pyridines 15, beginning with the 
reaction of oxime 11b and crotonic acid (14a, eq 4).  To our delight, pyridine 15ba is the only 
observed product in this case, indicating both selective alkene incorporation and complete 

































>20 : 1 regioselectivity





















































conditions for Rh(III)–catalyzed decarboxylative coupling of 11b and 14a by evaluating silver 
reagents and fluorinated alcohol solvents (Table 2.2).  In addition to TFE, 1,1,1,3,3,3–
hexafluoroisopropanol (HFIP) is a competent solvent for the reaction at 78 ºC (entry 2); 
decreased reactivity is observed at 58 ºC (entry 3).  Use of silver(II) oxide (AgO) as the 
stoichiometric oxidant results in 40% yield 15ba (entry 4), while the reaction with silver(I) oxide 
(Ag2O) affords 15ba in 15% yield (entry 5).  In fact, the reagent labeled silver(II) oxide or AgO 
likely exists as a 1:1 mixture of silver(I) and silver(III) species.19  Since Ag2O (silver(I)) is a less 
efficient oxidant for decarboxylative coupling of 11b and 14a, we wondered if addition of 2.1 
equivalents AgO (thus, 2.1 equivalents silver(III)) would benefit reactivity.  Actually, pyridine 
15ba forms in only 20% yield under these conditions (entry 6).  Finally, reactions conducted in 
both TFE and HFIP at 100 ºC lead to decreased product yields (entries 8 and 9). 
One major difference between the current transformation and our prior work is the 
stoichiometric amount of carboxylic acid (RCO2H).  Acid dissociation (RCO2H → RCO2– + H+) 
results in a negatively charged alkene component as well as a more acidic reaction medium: two 
changes that certainly could affect the desired reaction.  For this reason, we investigated the 
addition of acidic or basic reagents to the reaction of 11b and 14a, using high throughput 
experimentation (HTE) as an efficient means for screening additives (Figure 2.1).  Concentrating 
on the two effective catalyst/oxidant systems ([RhCp*Cl2]2/AgOAc and RhCp*(OAc)2/AgO) and 
two competent solvents (TFE and HFIP), twelve different additives were employed in both 
catalytic and stoichiometric amounts, constituting 96 different combinations.  General 
conclusions from the data shown in Figure 2.1 include:  a) use of acidic additives benefits 
reactivity and b) higher product yields are observed when HFIP is the solvent.  Specifically, 
addition of 1 equivalent p–toluenesulfonic acid (TsOH) to reactions in HFIP results in the 
! 46 
highest yields of 15ba observed in this screen.  AgO is as effective as AgOAc in this system, so 
we chose to continue our investigation using the less expensive reagent, AgO.  The benefit of 
adding 1 equivalent TsOH to the reaction of 11b and 14a on the small scale needed for HTE was 
confirmed using standard reaction setup on 0.12 mmol scale (entry 1, Table 2.3).  Since 
oxidation by AgO theoretically generates water, hygroscopic agents were also examined.  
Addition of 3Å molecular sieves or magnesium sulfate (MgSO4) under the previous conditions 
(entries 2 and 3) or in combination with 1 equivalent TsOH (entries 4 and 5) lends no 
improvement to the reaction.  Replacing TsOH with Amberlyst 15, a polymeric sulfonic acid, 
results in decreased reactivity (entry 6).  Addition of 1 equivalent methanesulfonic acid 
(MeSO3H) leads to formation of pyridine 15ba in 75% yield (entry 7), while complete 
decomposition of oxime substrate 11b occurs in the presence of excess MeSO3H (entry 8). 


















The positive effect of sulfonic acid additives has a few potential explanations, apart from 
acidity of the reaction medium.  For one, ligand exchange could afford a rhodium tosylate 
complex in situ, which may be more reactive.  To test this possibility, RhCp*(OTs)2 was 
prepared and employed in the otherwise standard reaction.  In this case, pyridine 15ba forms in 
45% yield (entry 3, Table 2.4), suggesting the enhanced reactivity is not due to generation of 
rhodium tosylate complex.  
Alternately, combination of 
AgO and TsOH could produce 
AgOTs in situ, perhaps 
providing a more effective 
oxidizing reagent.  Indeed, 
reaction of 11b and 14a in the 
presence of 2.1 equivalents 
AgOTs affords pyridine 16ba in 
75% yield (entry 4).  The 
greater solubility of AgOTs 
compared to AgO in the 
reaction medium offers one 
potential explanation for this 
difference in reactivity. 
We explored the scope 
of Rh(III)–catalyzed annulation 
of oxime 11b and various 












TsOH (1 equiv) + 3Å mol sieves 
TsOH (1 equiv) + MgSO4











aConditions: 1.2 equiv 14a, 0.3 M, 12 h. bDetermined by 1H NMR.
additive
HFIP, 80 °C
[RhCp*(OAc)2 (5 mol %)
AgO (1.05 equiv)
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Table 2.3. Sulfonic acid and hygroscopic additives.a
14a
HFIP, 80 °C
[RhCp*(OAc)2 (5 mol %)









Table 2.4. The effect of sulfonic acid additives.a
14a
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acrylic acid derivatives (14) in the presence of 1.05 equivalents AgO and 1 equivalent MeSO3H 
(Chart 2.1).  For each substrate, both [RhCp*Cl2]2 and RhCp*(OAc)2 precatalysts were 
evaluated, although no significant differences were observed.  Decarboxylative coupling of a 
variety of alkyl–substituted acrylic acids proceeds to complete conversion with >20:1 selectivity 
for 5–alkyl pyridines (15ba–15bd).  Reactions of aryl–substituted acrylic acids also favor 
formation of 5–substituted products (15be–15bh), but in lower yields.  In fact, significant 
decomposition of furyl substrate 14h occurs under the standard conditions as well as in control 
reactions.  For these reasons, a second examination of stoichiometric oxidants was conducted. 
Inspired by a recent report in which rhodium(I) precatalysts were activated by oxidation 
with benzoyl peroxide,20 we evaluated potential peroxy–type oxidants (Table 2.5).  Various 

























































Me X = OAc
5% yield N
Me






aConditions: 1.2 equiv 14, 0.3 M, 12 h. bYields determined by 1H NMR. cWith (Z)-cinnamic acid.
15




15ba 15bb 15bc 15bd
15be 15bf 15bg 15bh
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process is incomplete and picolinic acid 20ba is observed in these cases.  Furthermore, pyridine 
products undergo additional oxidation to pyridine N–oxides 19 under these conditions.  On the 
other hand, over–oxidation to 19 does not occur in the presence of potassium peroxymonosulfate 
(KHSO5, entry 5) or potassium persulfate (K2S2O8, entry 6).  These reactions afford mixtures of 
the desired pyridine 15ba and picolinic acid 20ba.  We elected to continue our study using 






























[RhCp*(OAc)2 (5 mol %)




























Table 2.5. Investigation of peroxy-type oxidants.a
K2S2O8 (1.05 equiv)
HFIP, 80 °C













































[RhCp*(OAc)2 (5 mol %)






Table 2.6. Silver additive screen.a
CO2H
! 50 
K2S2O8 as the stoichiometric oxidant since less substrate decomposition is observed in this case.   
We hypothesized combination of K2S2O8 and substoichiometric silver reagents would 
favor the desired decarboxylative process (Table 2.6).  Indeed, addition of 0.25 equivalents 
AgOTs enhances selectivity for pyridine 15ba, resulting in a 10:1 mixture of 15ba and 20ba 
(entry 1); however, conversion is incomplete in this case.  The yield of 15ba increases with 
greater amounts of silver additive, and use of 0.8 equivalents AgOTs proves optimal (entry 4).  
Reactions employing other silver(I) salts with non–coordinating counterions afford 15ba in 
slightly lower yields (entries 6 and 7) and use of excess K2S2O8 is not beneficial (entry 8).! 
These newly optimized conditions proved unsatisfactory for Rh(III)–catalyzed annulation 
of oxime 11b and 
(hetero)aryl acrylic acids 
14h and 14i (eq 5).  We 
evaluated the effects of 
modifying the 
cyclopentadienyl ligand 
of the rhodium catalyst 
in the reaction of oxime 
11b and 3–
(methoxy)cinnamic acid 
(14i, Chart 2.2).  
Fortunately, use of 
electron deficient 




Ar = 2-furyl → 15bh, 15% yield






































aConditions: 1.2 equiv 14i, 0.3 M, 12 h. bYields determined by 1H NMR.
15bi
Chart 2.2. Catalyst screen with alkene 14i.a,b
K2S2O8 (1.05 equiv)
HFIP, 80 °C
[RhCp*(OAc)2 (5 mol %)










70% yield of 5–aryl pyridine 15bi.  Furthermore, employing [RhCpCF3Cl2]2 in reactions of 
various oxime substrates 11 and substituted acrylic acids 14 leads to full conversion at 58 ºC 
(Charts 2.3 and 2.4).  
 
2.2.2 Substrate Scope  
With optimized 
conditions in hand, we 
explored the scope of oxime 
substrates 11 in the reaction 
of non–2–enoic acid (14j, 
Chart 2.3).  α,β–Unsaturated 
oxime esters containing α–
alkyl and α–aryl substitution 
undergo decarboxylative 
coupling to afford 5–
substituted pyridines (15) 
with >20:1 selectivity and 
good yield.  As in the 
analogous reaction of 
terminal alkenes, reactivity 
decreases in the case of ethyl vinyl oxime ester 11e, and use of β–substituted oxime substrate 11f 
leads to no desired product.  Furthermore, elimination of PivOH affords nitrile 21 in the reaction 
of aldoxime ester 11g (eq 6). 
N OPiv

















































Chart 2.3. Unsaturated oxime ester scope.a






Rh(III)–catalyzed annulation of 11b proceeds with a variety of acrylic acid derivatives 
(14, Chart 2.4), conveniently accessed by Knoevenagel condensation of the appropriate aldehyde 
and malonic acid.21  Both primary and secondary alkyl–substituted derivatives participate to 
access 5–alkyl pyridines 15 in good yield and with >20:1 selectivity.  The acrylic acid substrate 
may also bear aryl or heteroaryl substitution.  While the alkene component contains two 
























Chart 2.4. Substituted acrylic acid scope.a

































































Reactions of cinnamic acid (15e) as well as 3–(methyl) and 2–, 3–, and 4–(methoxy)cinnamic 
acid derivatives proceed with complete conversion to 5–aryl pyridine products.  On the other 
hand, electron deficient 4–(nitro) and 4–(trifluoromethyl)cinnamic acids (14p and 14q) are 
unreactive substrates.  Use of 0.5 
equivalent AgOTs is optimal for 
decarboxylative coupling of 10b 
and heteroaryl acrylic acid 
substrates 15h, 15s, and 15t, 
although yields are lower in these 
cases.  Interestingly, reaction of 
11b and 14u does not afford 
pyridine 15bu but reduced 
product 15ba in 70% yield (eq 
7).  This overall redox–neutral 
























































[RhCpCF3Cl2]2 (2.5 mol %)
AgOTs (0.9 equiv)
K2S2O8 (1.05 equiv)
HFIP, 58 °C 17a













aConditions: 1.2 equiv 16, 0.3 M. bDetermined by 1H NMR.
change from standard conditions
none
AgOTs (2.1 equiv), no K2S2O8
AgOAc (2.1 equiv), no K2S2O8
[RhCp*Cl2]2 (2.5 mol %)
HFIP, 80 °C
TFE, 74 °C
















external oxidant, and 15ba forms in 50% yield in the absence of K2S2O8 using catalytic AgOTs 
(eq 8).   
 Surprisingly, optimization of conditions for Rh(III)–catalyzed coupling of oximes 11 and 
β–substituted acrylic acids 14 proved detrimental in the reaction of acrylic acid (16, entry 1, 
Table 2.7).  We investigated this change by alternating several reaction parameters separately 
(Table 2.7).  That is, use of the previous oxidant (AgOAc, entry 3) or catalyst ([RhCp*Cl2]2, 
entry 4) leads to similarly low yields of pyridine 17a.  On the other hand, performing the reaction 
at elevated temperature (entry 5) and in TFE (entry 6) recovers reactivity.  Using these 
conditions, decarboxylative coupling of oxime 11c and acrylic acid (16) affords disubstituted 
pyridine 17c in 77% isolated yield (eq 9). 
 
2.2.3 Mechanistic Studies 
 Early mechanistic experiments aimed to elucidate the mechanism of the decarboxylation 
step.  We considered a pathway involving initial Rh(III)–catalyzed annulation of 11 and 14 to 
access picolinic acid intermediate 20, followed by in situ decarboxylation, perhaps assisted by 
the silver(I) reagent, to afford observed pyridine product 15 (Scheme 2.5).  Indeed, silver(I)–
catalyzed decarboxylation is an established process that has been demonstrated for both aromatic 
and heteroaromatic carboxylic acid substrates.9b–d  However, preliminary observations were not 






















Scheme 2.5. Decarboxylation of a picolinic acid intermediate.
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reaction of 11b and 14a by 1H NMR spectroscopy indicates picolinic acid 20ba is not present in 
observable amounts at 20, 45, 90, or 180 minutes (eq 10).  Furthermore, pyridine 15ba forms 
alongside picolinic acid 20ba in the absence of Ag(I) reagent (eq 11), implying Ag(I) is not a 
prerequisite for decarboxylation.   
To confirm Rh(III)–catalyzed decarboxylative coupling does not involve the process 
illustrated in Scheme 2.5, potential intermediate 20aa was prepared (eq 12).  In fact, we took 
advantage of our previously developed conditions for Rh(III)–catalyzed coupling of oxime 11a 








































































































[RhCp*Cl2]2 (2.5 mol %)
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esters like 23.  Subsequent basic hydrolysis provides the desired picolinic acid 20aa.  In the 
reaction of 11b and 14a in the presence of 1 equivalent 20aa, decarboxylation of the picolinic 
acid does not occur and a quantitative amount of 20aa is recovered.  This result provides strong 
evidence that decarboxylative coupling does not proceed via a picolinic acid intermediate 20 
(Scheme 2.5).!!
We also considered decarboxylation by a single electron transfer mechanism.  K2S2O8 is 
often used in combination with Ag(I) catalysts for decarboxylative coupling reactions of 
carboxylic acid derivatives (Scheme 2.6).22  The decarboxylation process is proposed to proceed 
by single electron transfer from Ag(I) to S2O82–, generating Ag(II) and persulfate radical (SO4–!, 
eq 14).23  Either species may abstract an electron from the carboxylate group, resulting in loss of 
CO2 to form a radical species [R!] (eq 15 and 16) that undergoes functionalization.  Actually, 
S2O82– may gain an electron from a variety of sources, so a Ag(I) catalyst is not necessarily 
required for reactivity.  In Ag(I)/S2O82––catalyzed decarboxylative coupling, aryl carboxylic 
acids are typically less reactive than alkyl substrates, a difference that presumably results from 
stability of the radical intermediate 
([R!]).  For example, Cheng and Li 
demonstrated Ag(I)/S2O82––catalyzed 
decarboxylative alkynylation only 
proceeds with the alkyl carboxylic acid 
group in substrate 24, resulting in 
exclusive formation of 26 (eq 17).22   
Decarboxylation by a single electron transfer pathway could explain the amount of 
pyridine 15ba produced in the absence of Ag(I) (eq 11), as well as the enhanced selectivity for 
AgI   +   S2O82- AgII   +   SO4−    +   SO42-













Scheme 2.6. Ag(I)/S2O82- assisted decarboxylation.
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15ba in the presence of Ag(I) additives (Table 2.6).  A possible decarboxylation pathway is 
illustrated in Scheme 2.7.  Here, single electron abstraction from alkyl carboxylate III and loss of 
CO2 affords radical species IV.  If this pathway were operative, then decarboxylative coupling of 
11b and alkene–tethered 14v (eq 18) could generate bicyclic product 27 via 5–exo–trig radical 
cyclization from the corresponding intermediate IV.  In fact, pyridine 15bv is the only product 
observed in the reaction of 11b and 14v (eq 18).  This result, however, does not conclusively rule 
out decarboxylation by the pathway shown in Scheme 2.7. 
We gained further insight regarding the mechanism of pyridine formation from isotope 
studies.  Specifically, reaction of 11b and 14a conducted in TFE–d (F3CCH2OD) leads to 
deuterium incorporation at the β–position in 11a–d after 30% conversion, providing evidence for 













































































15ba–dn but not at the corresponding position in 11b–d.  Our prior mechanistic work showed 
deuterium incorporation does not occur by reversible deprotonation of the pyridine product 
(Chapter 1, eq 25).  These observations are consistent with reversible deprotonation en route to 
the pyridine product, after the first irreversible step of the reaction mechanism.  Furthermore, the 
relatively lower amount of deuterium incorporation at the 2–methyl substituent in the reaction of 
crotonic acid (14a, 31% D) versus ethyl acrylate (23a, Chapter 1, eq 24, 88% D) suggests the 
carboxylic acid moiety is present during the deprotonation step. 
Stoichiometric reactions provided a wealth of information regarding the mechanism of 
pyridine formation by Rh(III)–catalyzed decarboxylative coupling of unsaturated oxime esters 
and substituted acrylic acids.  After 90 minutes at 58 ºC, the reaction of 11b, 14a, and 1 
equivalent RhCp*(OAc)2 affords not the pyridine product, but a mixture of rhodium carboxylate 
complexes 28 (eq 20).  Structures of 28 were tentatively assigned based on NMR, IR, and mass 
spectroscopy.   
Purification of rhodium complexes 28 proved difficult, so alternate strategies were 
explored.  We hypothesized exchange of carboxylate ligands for chloride would provide a more 
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excess LiCl to a solution of crude complexes 28 in Et2O affords an insoluble pale orange solid.  
Dissolving in CH2Cl2 and separation from LiCl by filtration leads to pure rhodium chloride 
complex 29 (eq 21).  However, conversion is low in this case, even during prolonged reaction 
times.  On the other hand, rapid ligand exchange occurs in the presence of excess trimethylsilyl 
chloride (TMSCl); in fact, both carboxylate ligands are replaced to afford precatalyst 
[RhCp*Cl2]2 (eq 22).  Use of 1 equivalent TMSCl allows selective exchange with the non–
tethered carboxylate ligand, affording rhodium chloride 29 in 68% yield (eq 23).  The pure 
complex 29 was characterized by NMR, IR, and mass spectroscopy.  A few data points were 
troubling: a) Coupling between 5–H and 6–H (eq 23) has a particularly large J value (15.6 Hz).  
b) 4–H does not couple to 5–H.  Fortunately, slow evaporation from a concentrated solution of 
29 in CH2Cl2 afforded red orange crystals suitable for X–ray analysis.  The crystal structure of 
29 (Figure 2.2) 
confirms the structure 
shown in Scheme 2.8 
and, by analogy, the 
structure of 28 given in 
eq 20.  Furthermore, 
crystallographic data 
indicates a dihedral 
angle between C5–H 
and C6–H bonds close 
to 180º, explaining the 
large J value, as well as 














































































a dihedral angle between C4–H and 
C5–H bonds near 90º, consistent with 
a small (in this case, unobservable) 
coupling constant.  Importantly, in 29, 
C–N bond formation has taken place 
but decarboxylation has not yet 
occurred, lending insight to the timing 
of the decarboxylation step in the 
reaction mechanism (vide infra). 
Metalacycle decomposition studies contributed further mechanistic insight (Scheme 2.9).  
Crude carboxylate complexes 28 are stable in solution at room temperature, but heating to 58 ºC 
results in complete conversion to a 1:1.7 mixture of pyridine 15ba and picolinic acid 20ba after 
12 hours (eq 24).  This observation suggests a complex analogous to 28 is a common 
intermediate of both observed products.  Contrastingly, conversion of pure chloride complex 29 
is sluggish, reaching only 40% conversion after 24 hours (eq 25).  Furthermore, decomposition 
of 29 favors formation of picolinic acid 20ba, leading to a 1:3 mixture of 15ba and 20ba.  To 
rule out any influence of impurities in the decomposition of crude carboxylate complexes 28, we 
targeted the synthesis of pure rhodium acetate 30.  Silver(I)–promoted ligand exchange of 
rhodium chloride 29 with AgOAc proved to be the easiest strategy, affording acetate complex 30 
in 80% yield (see Appendix 2).  Like the reaction of 29, decomposition of 30 is slow, resulting in 
60% conversion after 24 hours (eq 26).  Importantly, pyridine and picolinic acid products 15ba 
and 20ba form as a 1:1 mixture in this case.  The difference in product distributions in 
decomposition reactions of rhodium chloride 29 compared to acetate complex 30 suggests 
Figure 2.2. X-ray crystal structure of 29.24
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identity of the X–type ligand at this stage in the mechanism influences the divergence of reaction 
pathways to the two observed products.   
We propose formation of pyridine 15ba and picolinic acid 20ba by Rh(III)–catalyzed 
decarboxylative coupling of 11b and 14a in the absence of Ag(I) proceeds by the mechanism 
shown in Figure 2.3.  After generation of active carboxylate catalyst I, dissociation of an acetate 
ligand opens a site for coordination by the oxime substrate 11b, resulting in cationic complex II.  
Reversible C–H activation at the β–position affords metalacycle III.  Coordination and migratory 
insertion of 14a installs the electron–withdrawing carboxylic acid moiety α to the metal center in 
7–membered rhodacycle IV.  Deprotonation of the carboxylic acid and chelation provides 
neutral complex V.  C–N bond formation/N–O bond cleavage affords rhodium carboxylate VI 







































































1 : 3.0 15ba/20ba
40% conversion
15ba 20ba
1 : 1.0 15ba/20ba
60% conversion
15ba 20ba
Scheme 2.9. Decomposition of complexes 28, 29, and 30.
! 62 
that is related to complexes 28, 29, and 30.  At this point, protonation and ligand dissociation 
may occur to liberate either of the two carboxylate ligands, accessing cationic complex VIIa or 
VIIb.  From VIIa, deprotonation leads to intermediate VIIIa that may undergo retro–[2+2+1] 
cycloaddition to extrude CO2 and pyridine product 15ba.  Alternatively, from VIIb, 
deprotonation and subsequent β–hydride elimination provides picolinic acid 20ba and Rh(I) 
species IX that is oxidized to regenerate active catalyst I.   
It is clear the Ag(I) reagent plays a major part in both selectivity and reactivity in 
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acrylic acids (Table 2.6).  The exact role of Ag(I) in the reaction mechanism is not fully 
understood at this time, but the following observations have provided some insight.  Reaction of 
acetate complex 30 in the presence of 1 equivalent AgOTs leads to exclusive formation of 
pyridine 15ba (eq 27).  This result suggests Ag(I) becomes involved after formation of an 
intermediate analogous to 30 (i.e. VI in Figure 2.3).  Additionally, selective decarboxylative 
coupling in not limited to Ag(I) additives.  Specifically, only a trace amount of picolinic acid 
20ba is observed in the reaction of 11b and 14a in the presence of 1 equivalent Cs2SO4 (eq 28). 
 
2.3 Conclusion 
 In conclusion, we developed a complementary method for pyridine synthesis by 
rhodium(III)–catalyzed decarboxylative coupling of α,β–unsaturated O–pivaloyl oxime esters 
and acrylic acid derivatives.  Carboxylic acids function as traceless activating groups, allowing 
selective formation of 5–substituted pyridine products.  Mechanistic studies strongly suggest 
pyridine formation does not proceed via a picolinic acid intermediate.  Stoichiometric 
experiments allow characterization of catalytically relevant rhodium complexes that provide 



















































evidence for C−N bond formation before the decarboxylation step.  Metalacycle decomposition 
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A.1.1 General Methods 
All reactions were carried out in oven-dried glassware under an atmosphere of argon with 
magnetic stirring.  ACS grade acetic acid and 2,2,2-trifluoroethanol and reagent grade silver 
acetate were purchased from Sigma-Aldrich Co. and used without further purification.  1,2-
Dichloroethane was distilled from calcium hydride under an atmosphere of argon.  Alkenes 15k-
m, 15o-q, 15t, 15w, 32a, (E)-32b, 32c-f, (E)-32g and 32h were purchased and used without 
further purification.  Substrates 15v,1 trans- and cis-15x,2 (Z)-32b3 and (Z)-32g4 were prepared as 
previously reported.  Alkenes 15r, 15s and 15u were distilled and alkenes 15a-j and 15n were 
distilled under reduced pressure prior to use.  [RhCp*Cl2]2 was prepared as previously reported.5  
Column chromatography was performed on Silicycle® SilicaFlash® P60 (230-400 mesh).  Thin 
layer chromatography was performed on Silicycle® 250µm silica gel 60A plates.  Visualization 
was accomplished with UV light (254 nm) or potassium permanganate. 
1H NMR and 13C NMR spectra were collected at ambient temperature in CDCl3 on a 
Varian 400 MHz.  Chemical shifts are expressed as parts per million (δ, ppm) and are referenced 
to 7.26 (CHCl3) for 1H NMR and 77.16 (CDCl3) for 13C NMR.  Proton signal data uses the 
following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet and J = 
coupling constant.  Mass spectra were obtained on a Fisons VG Autospec (HRMS) or an Agilent 
Technologies 6130 Quadropole Mass Spec (LRMS).  Infrared spectra were collected on a Bruker 
Tensor 27 FT-IR spectrometer.   
Regioisomeric ratios were determined by integration of 1H NMR spectra of product 
mixtures collected with first relaxation delay (d1) = 15 seconds.  The major product of the 
reaction of 24f and 32d was identified as 33fd by 1H-13C HSQC and 1H-13C HMBC.  
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A.1.2 Synthesis of Oxime Ester Precursors 
The α,β-unsaturated ketone precursors of 24a-c, 24h, and 24l as well as 24f were 
purchased from Sigma-Aldrich Co. and Tokyo Chemical Industry Co., respectively.  Enone 
precursors corresponding to 24d and 24e were prepared as previously reported.6  The precursors 
of 24g and 24i-k were obtained by methylenation of the appropriate ketones by the following 
procedure, adapted from the literature.7  A solution of the ketone (20 mmol), aqueous 
formaldehyde (4.9 mL, 3 equiv) and morpholine (0.86 mL, 0.5 equiv) in 18 mL acetic acid was 
heated at 120 °C for 20 hours.  After cooling, the mixture was neutralized with 3M NaOH and 
extracted with diethyl ether three times.  The combined organic layers were washed with 
saturated NaHCO3 and brine, dried over MgSO4, filtered and concentrated in vacuo.  The crude 
product was purified by flash column chromatography. 
 
A.1.3 General Procedure for Oxime Ester Synthesis 
All O-pivaloyl oxime esters 24 were generated from the corresponding α,β-unsaturated 
ketones according to the following procedure, adapted from the literature.8  Hydroxylamine 
hydrochloride (347 mg, 7 mmol, 1.4 equiv) and Na2CO3 (742 mg, 7 mmol, 1.4 equiv) were 
added to the enone (5 mmol) in 15 mL MeOH and the mixture was stirred at 65 °C for 1 hour (or 
room temperature for 4 hours for 24i and 24l).  The solvent was removed in vacuo and the 
resulting residue was dissolved in 10 mL CH2Cl2 and cooled to 0 °C.  After the addition of Et3N 
(1.74 mL, 12.5 mmol, 2.5 equiv), a solution of pivaloyl chloride (1.23 mL, 10 mmol, 2 equiv) in 
5 mL DCM was added dropwise at 0 °C.  The mixture was stirred at room temperature overnight 
and quenched with water.  The aqueous layer was extracted with CH2Cl2 three times and the 
combined organic layers were washed with saturated NaHCO3 and brine, dried over MgSO4, 
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filtered and concentrated in vacuo.  The crude product was purified by flash column 
chromatography. 
(E)-1-(cyclohex-1-en-1-yl)ethanone O-pivaloyl oxime (24a).  White 
solid.  Rf = 0.25 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 
6.35 (m, 1H), 2.40 (m, 2H), 2.20 (m, 2H), 2.07 (s, 3H), 1.63 (m, 4H), 1.29 
(s, 9H).  13C NMR (100 MHz, CDCl3) δ 175.3, 164.1, 134.6, 133.5, 38.9, 27.4, 26.3, 24.6, 22.2, 
22.0, 12.0.  IR (NaCl, thin film) ν 2936, 1759, 1638, 1590, 1480, 1294, 1114, 917, 804 cm-1.  
HRMS (ESI) m/z [2M+Na] calcd 469.3042, found 469.3046.  
(2E,3E)-4-phenylbut-3-en-2-one O-pivaloyl oxime (24b).  Pale yellow 
viscous liquid.  Rf = 0.21 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 7.48 (d, J = 7.2 Hz, 2H), 7.38-7.30 (m, 3H), 7.08 (d, J = 17.2 Hz, 
1H), 7.04 (d, J = 16.8 Hz, 1H), 2.23 (s, 3H), 1.33 (s, 9H).  13C NMR (100 MHz, CDCl3) δ 175.1, 
162.9, 137.3, 135.8, 129.3, 129.0, 127.3, 124.7, 38.9, 27.4, 11.7.  IR (NaCl, thin film) ν 2974, 
1749, 1633, 1587, 1479, 1272, 1112, 904, 751 cm-1.  HRMS (ESI) m/z [2M+Na] calcd 513.2729, 
found 513.2732.  
(2E,3E)-non-3-en-2-one O-pivaloyl oxime (24c).  Pale yellow viscous 
liquid.  Rf = 0.24 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 
6.35-6.25 (m, 2H), 2.22-2.17 (m, 2H), 2.07 (s, 3H), 1.47-1.40 (m, 2H), 
1.34-1.24 (m, 4H), 1.29 (s, 9H), 0.88 (t, J = 6.8 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 175.2, 
163.0, 141.2, 126.5, 38.9, 33.0, 31.4, 28.4, 27.4, 22.6, 14.1, 11.7.  IR (NaCl, thin film) ν 2931, 














(2E,3E)-3-methyl-4-phenylbut-3-en-2-one O-pivaloyl oxime (24d).  
Pale yellow viscous liquid.  Rf = 0.28 (10:1 hexanes/EtOAc).  1H NMR 
(300 MHz, CDCl3) δ 7.41-7.29 (m, 5H), 7.05 (bs, 1H), 2.25 (s, 3H), 2.19 
(s, 3H), 1.33 (s, 9H). 
(2E,3E)-3-methylnon-3-en-2-one O-pivaloyl oxime (24e).  Pale yellow 
viscous liquid.  Rf = 0.35 (10:1 hexanes/EtOAc).  1H NMR (300 MHz, 
CDCl3) δ 6.07 (t, J = 7.2 Hz, 1H), 2.21 (q, J = 7.2 Hz, 2H), 2.10 (s, 3H), 
1.94 (s, 3H), 1.47-1.38 (m, 2H), 1.34-1.26 (m, 4H), 1.30 (s, 9H), 0.89 (t, J = 6.9 Hz, 3H). 
(E)-3-methylbut-3-en-2-one O-pivaloyl oxime (24f).  Colorless liquid.  
Rf = 0.43 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 5.54 (m, 
1H), 5.43 (m, 1H), 2.12 (s, 3H), 2.05 (s, 3H), 1.30 (s, 9H).  13C NMR (100 
MHz, CDCl3) δ 175.2, 163.7, 141.0, 120.6, 38.9, 27.4, 19.3, 12.2.  IR (NaCl, thin film) ν 2976, 
1762, 1480, 1270, 1108, 921 cm-1.  HRMS (ESI) m/z [M+H] calcd 184.1338, found 184.1331. 
(E)-3-methyleneheptan-2-one O-pivaloyl oxime (24g). Colorless liquid. 
Rf = 0.45 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 5.53 (s, 
1H), 5.38 (m, 1H), 2.44 (td, J = 7.6, 1.2 Hz, 2H), 2.10 (s, 3H), 1.50 (m, 
2H), 1.34 (m, 2H), 1.30 (s, 9H), 0.90 (t, J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 175.1, 
163.5, 145.4, 119.1, 38.9, 32.0, 30.6, 27.4, 22.6, 14.1, 12.8.  IR (NaCl, thin film) ν 2960, 1763, 
1480, 1270, 1107, 920 cm-1.  HRMS (ESI) m/z [M+Na] calcd 248.1626, found 248.1622. 
(E)-1-(cyclopent-1-en-1-yl)ethanone O-pivaloyl oxime (27h).  Colorless 
liquid. Rf = 0.33 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 
6.35 (m, 1H), 2.68 (m, 2H), 2.48 (m, 2H), 2.14 (s, 3H), 1.94 (m, 2H), 1.29 





















13.3.  IR (NaCl, thin film) ν 2971, 1760, 1480, 1272, 1113, 891 cm-1.  HRMS (ESI) m/z [M+H] 
calcd 210.1494, found 210.1495.  
(E)-3-phenylbut-3-en-2-one O-pivaloyl oxime (24i). White solid.  Rf = 
0.26 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.38-7.30 (m, 
5H), 5.70 (d, J = 0.8 Hz, 1H), 5.58 (d, J = 0.4 Hz, 1H), 2.09 (s, 3H), 1.33 
(s, 9H).  13C NMR (100 MHz, CDCl3) δ 175.1, 165.4, 145.2, 137.5, 128.6, 128.4, 127.9, 119.4, 
39.0, 27.5, 15.6.  IR (NaCl, thin film) ν 2980, 1752, 1584, 1367, 1267, 1110, 1031, 947, 896, 
776, 695 cm-1.  HRMS (ESI) m/z [M+Na] calcd 268.1313, found 268.1312. 
(E)-6-chloro-3-methylenehexan-2-one O-pivaloyl oxime (24j).  
Colorless liquid.  Rf = 0.33 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 5.62 (s, 1H), 5.49 (m, 1H), 3.55 (t, J = 6.4 Hz, 2H), 2.62 (td, J = 
7.6, 1.2 Hz, 2H), 2.12 (s, 3H), 2.04 (m, 2H), 1.30 (s, 9H).  13C NMR (100 MHz, CDCl3) δ 175.2, 
162.7, 143.6, 120.9, 44.7, 39.0, 31.4, 30.0, 27.4, 12.6.  IR (NaCl, thin film) ν 2971, 1761, 1480, 
1270, 1106, 1027, 921 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 246.1, found 246.1.   
(E)-4-methylenenonan-5-one O-pivaloyl oxime (24k).  Colorless liquid.  
Rf = 0.26 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 5.53 (s, 
1H), 5.38 (m, 1H), 2.55 (t, J = 8.0 Hz, 2H), 2.40 (td, J = 7.2, 1.2 Hz, 2H), 
1.57-1.35 (m, 6H), 1.29 (s, 9H), 0.92 (t, J = 7.2 Hz, 6H).  13C NMR (100 MHz, CDCl3) δ 175.2, 
167.3, 144.2, 119.1, 38.9, 34.7, 29.5, 27.4, 26.8, 23.1, 21.5, 13.9.  IR (NaCl, thin film) ν 2962, 













Pent-1-en-3-one O-pivaloyl oxime (24l).  Pale yellow liquid, 5.1:1 
mixture of isomers.  Rf = 0.46 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 6.9 (dd, J = 18.0, 11.2 Hz, 1H), 6.52 (dd, J = 18.0, 11.2 Hz, 1H), 
5.80 (dd, J = 18.0, 0.8 Hz, 1H), 5.79 (d, J = 18.0 Hz, 1H), 5.67 (dd, J = 11.2, 0.8 Hz, 1H), 5.64 
(d, J = 10.8 Hz, 1H), 2.56 (m, 2H), 1.29 (s, 9H), 1.28 (s, 9H), 1.20 (t, J = 7.6 Hz, 3H), 1.13 (t, J = 
7.6 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 175.1, 167.5, 164.4, 132.2, 125.3, 125.2, 122.7, 
38.9, 27.4, 27.3, 24.1, 18.9, 12.3, 11.4.  IR (NaCl, thin film) ν 2977, 1762, 1481, 1271, 1110, 
1027, 899 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 184.1, found 184.2. 
 
A.1.4 General Procedure for Pyridine Synthesis 
A 0.5 dram vial was charged with oxime ester 24 (0.21 mmol) and AgOAc (73.6 mg, 
0.441 mmol, 2.1 equiv) and a solution of [RhCp*Cl2]2 (3.3 mg, 0.005 mmol, 0.025 equiv) and 
alkene 15 or 32 (0.252 mmol, 1.2 equiv) in 0.7 mL 2:1 DCE/AcOH was added.  The vial was 
flushed with argon, sealed and heated at 85 °C in an aluminum heating block for 14 hours.  The 
solids were filtered and the mixture was diluted with CH2Cl2 and washed with 15% aqueous 
Na2CO3.  The aqueous layer was extracted twice with CH2Cl2 and the combined organic layers 
were dried over MgSO4, filtered and concentrated in vacuo.  The crude product was purified by 
flash column chromatography.  
Compounds 13fh,9 13fu and 14fu,10 2911 and 3012 were previously characterized. 
3-Methyl-4,5,6,7-tetrahydrobenzo[d]isoxazole (23).  Colorless 
viscous liquid.  Rf = 0.34 (10:1 hexanes/EtOAc).  1H NMR (400 
MHz, CDCl3) δ 2.64 (tt, J = 6.4, 1.6 Hz, 2H), 2.33 (tt, J = 6.0, 1.6 








22.7, 22.6, 22.3, 19.3, 10.1.  IR (NaCl, thin film) ν 2938, 2856, 1642, 1466, 1321, 1201, 869, 
740 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 138.1, found 138.2. 
Ethyl 1-methyl-5,6,7,8-tetrahydroisoquinoline-3-carboxylate  
(13aa).  Pale yellow viscous liquid.  Rf = 0.13 (3:1 
hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 4.44 
(q, J = 7.2 Hz, 2H), 2.79 (t, J = 6.0 Hz), 2.66 (t, J = 6.4 Hz, 2H), 2.53 (s, 3H), 1.87 (m, 2H), 1.76 
(m, 2H), 1.42 (t, J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 166.0, 157.8, 147.0, 144.1, 
135.4, 124.0, 61.8, 29.6, 26.4, 22.8, 22.6, 22.0, 14.5.  IR (NaCl, thin film) ν 2944, 1708, 1589, 
1372, 1317, 1261, 1212, 1028, 789 cm-1.  HRMS (ESI) m/z [M+H] calcd 220.1338, found 
220.1339. 
Ethyl 5,6-dimethylpicolinate (13fa).  Pale yellow viscous liquid.  
Rf = 0.15 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 
7.85 (d, J = 7.6 Hz, 1H), 7.50 (d, J = 7.6 Hz, 1H), 4.43 (q, J = 7.2 
Hz, 2H), 2.57 (s, 3H), 2.32 (s, 3H), 1.40 (t, J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 
165.7, 157.9, 145.4, 137.7, 135.9, 123.0, 61.8, 23.0, 19.5, 14.4.  IR (NaCl, thin film) ν 2983, 
1716, 1460, 1369, 1312, 1249, 1188, 1135, 1025, 783, 718 cm-1.  HRMS (ESI) m/z [M+H] calcd 
180.1025, found 180.1025. 
Ethyl 5-butyl-6-methylpicolinate (13ga).  Yellow viscous liquid.  
Rf = 0.26 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 
7.87 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 4.44 (q, J = 7.2 
Hz, 2H), 2.64 (t, J = 7.6 Hz, 2H), 2.61 (s, 3H), 1.56 (m, 2H), 1.43-1.34 (m, 5H), 0.94 (t, J = 5.4, 














22.6, 22.5, 14.4, 14.0.  IR (NaCl, thin film) ν 2959, 1717, 1574, 1458, 1369, 1313, 1180, 1138, 
1028 cm-1.  HRMS (ESI) m/z [M+H] calcd 222.1494, found 222.1489. 
Ethyl 1-methyl-6,7-dihydro-5H-cyclopenta[c]pyridine-3-
carboxylate (13ha).  Pale yellow viscous liquid.  Rf = 0.12 (3:1 
hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 4.44 
(q, J = 7.2 Hz, 2H), 2.97 (t, J = 7.6 Hz, 2H), 2.91 (t, J = 7.2 Hz, 2H), 2.55 (s, 3H), 2.14 (dd, J = 
7.6, 7.6 Hz, 2H), 1.41 (t, J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 166.0, 154.5, 146.0, 
142.5, 119.6, 61.8, 33.0, 31.0, 24.3, 22.4, 14.5.  IR (NaCl, thin film) ν 2960, 1716, 1594, 1376, 
1329, 1224, 1030, 791 cm-1.  HRMS (ESI) m/z [M+H] calcd 206.1181, found 206.1175.  
Ethyl 6-methyl-5-phenylpicolinate (13ia).  Yellow viscous 
liquid.  Rf = 0.23 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 8.01 (d, J = 7.6 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.43 
(m, 3H), 7.32 (m, 2H), 4.49 (q, J = 7.2 Hz, 2H), 2.60 (s, 3H), 1.45 (t, J = 7.2 Hz, 3H).  13C NMR 
(100 MHz, CDCl3) δ 165.5, 156.7, 146.6, 140.5, 139.2, 138.0, 128.9, 128.7, 128.1, 122.7, 62.0, 
23.9, 14.5.  IR (NaCl, thin film) ν 2982, 1716, 1561, 1446, 1369, 1309, 1200, 1142, 1027, 861, 
763, 703 cm-1.  HRMS (ESI) m/z [M+H] calcd 242.1181, found 242.1179. 
Ethyl 5-(3-chloropropyl)-6-methylpicolinate (13ja).  Pale yellow 
viscous liquid.  Rf = 0.17 (3:1 hexanes/EtOAc).  1H NMR (400 
MHz, CDCl3) δ 7.90 (d, J = 7.6 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 
4.45 (q, J = 7.2 Hz, 2H), 3.56 (t, J = 6.0 Hz, 2H), 2.85 (t, J = 7.6 Hz, 2H), 2.64 (s, 3H), 2.06 (m, 
2H), 1.42 (t, J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 165.5, 157.5, 145.9, 138.3, 137.2, 
123.1, 61.9, 44.2, 32.1, 30.0, 22.6, 14.5.  IR (NaCl, thin film) ν 2960, 1716, 1573, 1445, 1369, 
















Ethyl 6-butyl-5-propylpicolinate (13ka).  Pale yellow viscous 
liquid.  Rf = 0.47 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 7.78 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 4.37 
(q, J = 7.2 Hz, 2H), 2.81 (t, J = 8.0 Hz, 2H), 2.58 (t, J = 8.0 Hz, 2H), 1.66-1.52 (m, 4H), 1.36 (m, 
2H), 1.34 (t, J = 7.2 Hz, 3H), 0.92 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H).  13C NMR (100 
MHz, CDCl3) δ 165.8, 161.2, 145.6, 139.4, 137.3, 122.7, 61.7, 35.0, 34.4, 32.0, 23.7, 23.0, 14.5, 
14.1.  IR (NaCl, thin film) ν 2960, 1717, 1572, 1456, 1369, 1312, 1178, 1138, 1024 cm-1.  
HRMS (ESI) m/z [M+H] calcd 250.1807, found 250.1809. 
Ethyl 6-ethylpicolinate (13la).  Colorless viscous liquid.  Rf = 
0.07 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.93 
(dd, J = 7.6, 0.8 Hz, 1H), 7.73 (t, J = 7.6 Hz, 1H), 7.34 (dd, J = 
7.6, 0.8 Hz, 1H), 4.46 (q, J = 7.2 Hz, 2H), 2.93 (q, J = 7.6 Hz, 2H), 1.42 (t, J = 7.2 Hz, 3H), 1.32 
(t, J = 7.6 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 165.7, 164.3, 148.0, 137.3, 125.4, 122.6, 
61.9, 31.6, 14.5, 14.2.  IR (NaCl, thin film) ν 2976, 1718, 1591, 1463, 1368, 1235, 1139, 761  
cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 180.1, found 180.1. 
Benzyl 5,6-dimethylpicolinate (13fb).  Yellow viscous liquid.  Rf 
= 0.21 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.87 
(d, J = 7.6 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.48 (m, 2H), 7.38-
7.30 (m, 3H), 5.43 (s, 2H), 2.59 (s, 3H), 2.34 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 165.4, 
158.1, 145.1, 137.7, 136.1, 128.6, 128.5, 128.3, 123.2, 67.3, 23.0, 19.6.  IR (NaCl, thin film) ν 
2954, 1716, 1587, 1456, 1398, 1308, 1255, 1185, 1131, 1002, 782, 698 cm-1.  HRMS (ESI) m/z 
















Phenyl 5,6-dimethylpicolinate (13fc).  Off-white solid.  Rf = 
0.24 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.03 
(d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.42 (m, 2H), 7.26 
(m, 3H), 2.64 (s, 3H), 2.39 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 164.3, 158.3, 151.3, 144.7, 
137.9, 136.7, 129.5, 126.1, 123.9, 122.0, 23.1, 19.7.  IR (NaCl, thin film) ν 2923, 1732, 1591, 
1493, 1309, 1196, 1109, 746 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 228.1, found 228.1. 
N,N,5,6-Tetramethylpicolinamide (13fd).  Pale yellow viscous 
liquid.  Rf = 0.21 (EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.49 
(d, J = 8.0 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 3.11 (s, 3H), 3.07 (s, 
3H), 2.52 (s, 3H), 2.30 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 169.4, 156.0, 151.3, 138.1, 
132.7, 121.1, 39.2, 35.9, 22.5, 19.3.  IR (NaCl, thin film) ν 2926, 1637, 1575, 1441, 1397, 1274, 
1175, 1104, 843 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 179.1, found 179.1. 
1-(5,6-Dimethylpyridin-2-yl)ethanone (13fe).  Pale yellow 
viscous liquid.  Rf = 0.26 (5:1 hexanes/EtOAc).  1H NMR (400 
MHz, CDCl3) δ 7.78 (d, J = 7.6, 1H), 7.51 (d, J = 8.0, 1H), 2.70 
(s, 3H), 2.55 (s, 3H), 2.34 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 200.7, 156.8, 151.2, 137.7, 
136.0, 119.5, 25.9, 22.9, 19.6.  IR (NaCl, thin film) ν 2926, 1696, 1573, 1459, 1355, 1301, 1177, 
1122, 956, 839 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 150.1, found 150.2. 
(E)-2,3-Dimethyl-6-(2-styrylphenyl)pyridine (31h).  Pale yellow 
viscous liquid.  Rf = 0.66 (20:1 DCM/EtOAc).  1H NMR (400 
MHz, CDCl3) δ 7.75 (dd, J = 7.6, 1.6 Hz, 1H), 7.55 (dd, J = 7.2, 
2.0 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.41-7.19 (m, 9H), 7.04 (d, J 





















137.3, 135.9, 130.4, 129.7, 128.7, 128.4, 128.1, 127.8, 127.5, 126.7, 126.3, 122.7, 22.9, 19.1.  IR 
(NaCl, thin film) ν 2922, 1737, 1589, 1462, 1236, 1129, 961, 836, 761, 692 cm-1.  LRMS (ESI + 
APCI) m/z [M+H] calcd 286.2, found 286.2. 
2-Butyl-6-phenyl-3-propylpyridine (13kh).  Pale yellow viscous 
liquid.  Rf = 0.11 (1:1 hexanes/DCM).  1H NMR (400 MHz, 
CDCl3) δ 8.02 (m, 2H), 7.50-7.35 (m, 5H), 2.87 (t, J = 8.0 Hz, 2H), 
2.64 (t, J = 8.0 Hz, 2H), 1.82 (m, 2H), 1.66 (m, 2H), 1.48 (m, 2H), 1.02 (t, J = 7.2 Hz, 3H), 1.00 
(t, J = 7.6 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 160.1, 154.2, 137.4, 133.8, 128.7, 128.4, 
126.8, 117.7, 34.8, 34.2, 31.7, 23.9, 23.0, 14.3, 14.2.  IR (NaCl, thin film) ν 2959, 2871, 1585, 
1564, 1457, 1379, 833, 758, 693 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 254.2, found 
254.2. 
2-Butyl-6-(2-methoxyphenyl)-3-propylpyridine (13ki).  
Colorless viscous liquid.  Rf = 0.20 (10:1 hexanes/EtOAc).  1H 
NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 7.6, 1.6 Hz, 1H), 7.57 (d, 
J = 8.0 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.33 (ddd, J = 6.8, 6.8, 1.6 Hz, 1H), 7.07 (ddd, J = 7.6, 
7.6, 0.8 Hz, 1H), 6.98 (dd, J = 8.0, 0.8 Hz, 1H), 3.85 (s, 3H), 2.86 (t, J = 8.0 Hz, 2H), 2.63 (t, J = 
8.0, 2H), 1.77 (m, 2H), 1.66 (m, 2H), 1.47 (m, 2H), 1.03 (t, J = 7.6 Hz, 3H), 0.98 (t, J = 7.6 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ 159.9, 157.1, 152.7, 136.4, 133.2, 131.4, 129.4, 122.3, 
121.2, 111.5, 55.7, 34.9, 34.2, 32.1, 24.0, 23.1, 14.3.  IR (NaCl, thin film) ν 2958, 1585, 1493, 









2-Butyl-6-(3-methoxyphenyl)-3-propylpyridine (13kj).  
Colorless viscous liquid.  Rf = 0.45 (10:1 hexanes/EtOAc).  1H 
NMR (400 MHz, CDCl3) δ 7.62 (dd, J = 2.8, 1.6 Hz, 1H), 7.56 
(ddd, 7.6, 1.6, 1.2 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 
8.0 Hz, 1H), 7.36 (dd, J = 8.0, 8.0 Hz, 1H), 6.92 (ddd, J = 8.0, 2.8, 0.8 Hz, 1H), 3.89 (s, 3H), 
2.86 (t, J = 8.0 Hz, 2H), 2.63 (t, J = 8.0 Hz, 2H), 1.80 (m, 2H), 1.65 (m, 2H), 1.47 (m, 2H), 1.01 
(t, J = 5.4, 3H), 0.99 (t, J = 5.4, 3H).  13C NMR (100 MHz, CDCl3) δ 160.1, 153.9, 141.6, 137.4, 
134.0, 130.0, 119.3, 117.8, 114.2, 112.3, 55.4, 34.8, 34.2, 31.6, 23.9, 23.0, 14.3, 14.2.  IR (NaCl, 
thin film) ν 2958, 2871, 1566, 1463, 1222, 1048, 826, 782 cm-1.  HRMS (ESI) m/z [M+H] calcd 
284.2014, found 284.2015. 
2-Butyl-6-(4-methoxyphenyl)-3-propylpyridine (13kk).  
Colorless viscous liquid.  Rf = 0.43 (10:1 hexanes/EtOAc).  1H 
NMR (400 MHz, CDCl3) δ 7.96 (m, 2H), 7.43 (d, J = 8.0 Hz, 1H), 
7.41 (d, J = 8.0 Hz, 1H), 6.98 (m, 2H), 3.86 (s, 3H), 2.85 (t, J = 7.6 Hz, 2H), 2.61 (t, J = 7.6 Hz, 
2H), 1.80 (m, 2H), 1.64 (m, 2H), 1.47 (m, 2H), 1.00 (t, J = 7.2 Hz, 3H), 0.99 (t, J = 7.2 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 160.1, 160.0 153.9, 137.4, 133.0, 128.1, 117.0, 114.1, 55.5, 34.8, 
34.1, 31.7, 24.0, 23.0, 14.3, 14.2.  IR (NaCl, thin film) ν 2958, 1609, 1585, 1513, 1456, 1249, 
1181, 1032, 825 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 284.2, found 284.2. 
2-Butyl-6-(2-fluorophenyl)-3-propylpyridine (13kl).  Colorless 
viscous liquid.  Rf = 0.16 (1:1 hexanes/DCM).  1H NMR (400 
MHz, CDCl3) δ 8.04 (ddd, J = 8.0, 8.0, 2.0 Hz, 1H), 7.55 (dd, J = 
8.0, 2.4 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.33 (m, 1H), 7.25 (ddd, J = 7.6, 7.6, 1.2 Hz, 1H), 












2H), 1.66 (m, 2H), 1.47 (m, 2H), 1.02 (t, J = 7.2, 3H), 0.99 (t, J = 7.2, 3H).  13C NMR (100 MHz, 
CDCl3) δ 160.7 (d, J = 247.7 Hz), 160.4, 151.1 (d, J = 2.2), 137.0, 134.2, 131.2 (d, J = 3.1), 
129.8 (d, J = 8.4), 124.5 (d, J = 3.4), 121.8 (d, J = 9.2), 116.3, 116.0, 34.8, 34.2, 31.8, 23.9, 23.0, 
14.2.  IR (NaCl, thin film) ν 2959, 2872, 1585, 1491, 1455, 1387, 1212, 1109, 816, 757 cm-1.  
LRMS (ESI + APCI) m/z [M+H] calcd 272.2, found 272.2. 
2-Butyl-6-(3-chlorophenyl)-3-propylpyridine (13km).  Colorless 
viscous liquid.  Rf = 0.38 (1:1 hexanes/DCM).  1H NMR (400 
MHz, CDCl3) δ 8.03 (ddd, J = 2.0, 1.6, 0.4 Hz, 1H), 7.88 (ddd, J = 
7.2, 1.6, 1.6 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.37 (ddd, J = 8.0, 7.2, 
0.4 Hz, 1H), 7.33 (ddd, J = 8.0, 2.0, 1.6 Hz, 1H), 2.86 (t, J = 8.0 Hz, 2H), 2.63 (t, J = 8.0 Hz, 
2H), 1.80 (m, 2H), 1.65 (m, 2H), 1.48 (m, 2H), 1.01 (t, J = 7.2 Hz, 3H), 1.00 (t, J = 7.6 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 160.4, 152.6, 141.9, 137.5, 134.8, 134.5, 129.9, 128.4, 127.0, 
124.9, 117.7, 34.8, 34.2, 31.6, 23.9, 23.0, 14.2.  IR (NaCl, thin film) ν 2959, 2871, 1561, 1454, 
1379, 1078, 784 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 288.2, found 288.2. 
6-(4-Bromophenyl)-2-butyl-3-propylpyridine (13kn).  Colorless 
viscous liquid.  Rf = 0.63 (10:1 hexanes/EtOAc).  1H NMR (400 
MHz, CDCl3) δ 7.89 (m, 2H), 7.56 (m, 2H), 7.46 (d, J = 8.0 Hz, 
1H), 7.44 (d, J = 7.6 Hz, 1H), 2.85 (t, J = 7.6 Hz, 2H), 2.62 (t, J = 7.6 Hz, 2H), 1.78 (m, 2H), 
1.64 (m, 2H), 1.46 (m, 2H), 1.01 (t, J = 7.6 Hz, 3H), 0.98 (t, J = 7.6 Hz, 3H).  13C NMR (100 
MHz, CDCl3) δ 160.4, 152.9, 138.9, 137.5, 134.3, 131.8, 128.4, 122.8, 117.4, 34.8, 34.2, 31.6, 
23.9, 23.0, 14.3, 14.2.  IR (NaCl, thin film) ν 2958, 2930, 2871, 1586, 1454, 1377, 1072, 1009, 










2-Butyl-3-propyl-6-(3-(trifluoromethyl)phenyl)pyridine (13ko).  
Colorless viscous liquid.  Rf = 0.29 (10:1 hexanes/EtOAc).  1H 
NMR (400 MHz, CDCl3) δ 8.27 (s, 1H), 8.20 (d, J = 7.6 Hz, 1H), 
7.62 (d, J = 8.0 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.0, 1H), 
2.87 (t, J = 8.0 Hz, 2H), 2.64 (t, J = 8.0 Hz, 2H), 1.84-1.76 (m, 2H), 1.70-1.61 (m, 2H), 1.52-
1.43 (m, 2H), 1.01 (q, J = 7.6, 6H).  13C NMR (100 MHz, CDCl3) δ 160.6, 152.5, 140.8, 137.6, 
134.7, 131.1 (q, J = 32.3 Hz), 130.0, 129.2, 125.0 (q, J = 3.7 Hz), 124.5 (q, J = 270.9 Hz), 123.7 
(q, J = 4.0 Hz), 117.7, 34.8, 34.2, 31.6, 23.9, 23.0, 14.2, 14.2.  IR (NaCl, thin film) ν 2960, 2932, 
2873, 1570, 1458, 1442, 1380, 1336, 1270, 1166, 1127, 1072, 921, 835, 800, 697 cm-1.  LRMS 
(ESI + APCI) m/z [M+H] calcd 322.2, found 322.2. 
6-Hexyl-2,3-dimethylpyridine (13fr).  Pale yellow viscous liquid.  
Rf = 0.52 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 
7.29 (d, J = 7.6 Hz, 1H), 6.87 (d, J = 8.0 Hz), 2.70 (t, J = 7.6 Hz, 
2H), 2.47 (s, 3H), 2.23 (s, 3H), 1.67 (m, 2H), 1.37-1.25 (m, 6H), 0.87 (m, 3H).  13C NMR (100 
MHz, CDCl3) δ 159.1, 156.1, 137.4, 128.1, 119.8, 38.1, 31.7, 30.2, 29.1, 22.6, 22.5, 18.7, 14.1.  
IR (NaCl, thin film) ν 2926, 2857, 1578, 1467, 1397, 824 cm-1.  LRMS (ESI + APCI) m/z 
[M+H] calcd 192.2, found 192.2. 
5-Hexyl-2,3-dimethylpyridine (14fr).  Pale yellow viscous liquid.  
Rf = 0.26 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 
8.13 (d, J = 2.0 Hz, 1H), 7.20 (d, J = 1.6 Hz, 1H), 2.52 (t, J = 7.6 
Hz, 2H), 2.45 (s, 3H), 2.24 (s, 3H), 1.57 (m, 2H), 1.28 (m, 6H), 0.87 (m, 3H).  13C NMR (100 














IR (NaCl, thin film) ν 2928, 2857, 1474, 1412, 1139, 1020, 899, 727 cm-1.  LRMS (ESI + APCI) 
m/z [M+H] calcd 192.2, found 192.2. 
5-(tert-Butyl)-2,3-dimethylpyridine (14fs).  Yellow viscous 
liquid.  Rf = 0.10 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 8.35 (d, J = 2.4 Hz, 1H), 7.39 (d, J = 2.4 Hz, 1H), 2.46 
(s, 3H), 2.26 (s, 3H), 1.31 (s, 9H).  13C NMR (100 MHz, CDCl3) δ 154.0, 143.7, 143.6, 134.6, 
130.6, 33.2, 31.2, 22.0, 19.5.  IR (NaCl, thin film) ν 2962, 1481, 1397, 1167, 733 cm-1.  LRMS 
(ESI + APCI) m/z [M+H] calcd 164.1439, found 164.2. 
6-Cyclopentyl-2,3-dimethylpyridine (13ft).  Pale yellow viscous 
liquid.  Rf = 0.60 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 7.30 (d, J = 8.0, 1H), 6.93 (d, J = 8.0 Hz, 1H), 3.11 (m, 
1H), 2.47 (s, 3H), 2.23 (s, 3H), 2.07 (m, 2H), 1.81-1.66 (m, 6H).  13C NMR (100 MHz, CDCl3) δ 
162.6, 156.1, 137.5, 128.3, 118.3, 48.0, 33.9, 25.8, 22.8, 18.9.  IR (NaCl, thin film) ν 2952, 
2868, 1578, 1465, 1400, 1127, 825 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 176.1, found 
176.2. 
5-Cyclopentyl-2,3-dimethylpyridine (14ft).  Pale yellow viscous 
liquid.  Rf = 0.19 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 8.19 (d, J = 2.0 Hz, 1H), 7.25 (d, J = 2.0 Hz, 1H), 2.93 
(m, 1H), 2.45 (s, 3H), 2.25 (s, 3H), 2.05 (m, 2H), 1.82-1.50 (m, 
6H).  13C NMR (100 MHz, CDCl3) δ 154.4, 145.6, 139.1, 135.8, 130.9, 43.0, 34.6, 25.6, 22.2, 
19.4.  IR (NaCl, thin film) ν 2953, 2869, 1475, 1242, 1020, 892, 732 cm-1.  LRMS (ESI + APCI) 












6-(sec-Butyl)-2,3-dimethylpyridine (13fw).  Pale yellow viscous 
liquid.  Rf = 0.65 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 7.32 (d, J = 7.6 Hz, 1H), 6.87 (d, J = 7.6 Hz, 1H), 2.75 
(m, 2H), 2.47 (s, 3H), 2.23 (s, 3H), 1.72 (m, 1H), 1.57 (m, 1H), 1.24 (d, J = 7.2 Hz, 3H), 0.85 (t, 
J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 163.5, 156.1, 137.6, 128.4, 118.2, 43.4, 30.2, 
22.7, 20.7, 18.9, 12.3.  IR (NaCl, thin film) ν 2962, 2927, 1741, 1578, 1467, 1377, 1107, 827 cm-
1.  LRMS (ESI + APCI) m/z [M+H] calcd 164.1, found 164.2. 
5-(sec-Butyl)-2,3-dimethylpyridine (14fw).  Pale yellow viscous 
liquid.  Rf = 0.23 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 8.14 (bs, 1H), 7.22 (bs, 1H), 2.56 (m, 1H), 2.47 (s, 3H), 
2.26 (s, 3H), 1.58 (m, 2H), 1.22 (d, J = 7.2 Hz, 3H), 0.82 (t, J = 7.2 Hz, 3H).  13C NMR (100 
MHz, CDCl3) δ 154.3, 145.3, 140.1, 135.7, 131.0, 38.6, 30.9, 21.9, 21.6, 19.2, 12.1.  IR (NaCl, 
thin film) ν 2963, 2926, 2875, 1740, 1459, 1376, 1240, 1111, 1019, 898, 733 cm-1.  LRMS (ESI 
+ APCI) m/z [M+H] calcd 164.1, found 164.2.  
6-(trans-4-(tert-butyl)cyclohexyl)-2,3-dimethylpyridine (trans-
13fx).  Pale yellow viscous liquid.  Rf = 0.44 (5:1 hexanes/EtOAc).  
1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 8.0 Hz, 1H), 6.88 (d, J = 
8.0 Hz, 1H), 2.58 (tt, J = 12.4, 3.2 Hz, 1H), 2.46 (s, 3H), 2.26 (s, 
3H), 2.03-1.99 (m, 2H), 1.90-1.86 (m, 2H), 1.45 (q, J = 12.8 Hz, 2H), 1.22-1.05 (m, 3H), 0.87 (s, 
9H).  13C NMR (100 MHz, CDCl3) δ 163.2, 155.9, 137.4, 128.3, 117.6, 47.7, 46.3, 33.6, 32.4, 
27.4, 22.6, 18.8.  IR (NaCl, thin film) ν 2937, 2856, 1577, 1465, 1449, 1364 cm-1.  LRMS (ESI + 















14fx).  Pale yellow viscous liquid.  Rf = 0.09 (5:1 hexanes/EtOAc).  
1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 2.0 Hz, 1H), 7.22 (d, J = 
1.6 Hz, 1H), 2.45 (s, 3H), 2.40 (tt, J = 12.0, 3.2 Hz, 1H), 2.25 (s, 
3H), 1.93-1.88 (m, 4H), 1.42 (q, J = 12.4 Hz, 2H), 1.20-1.04 (m, 
3H), 0.88 (s, 9H).  13C NMR (100 MHz, CDCl3) δ 154.4, 145.2, 140.2, 135.5, 130.8, 47.6, 41.5, 
34.6, 32.5, 27.6, 22.0, 19.2.  IR (NaCl, thin film) ν 2938, 2855, 1475, 1448, 1365 cm-1.  LRMS 
(ESI + APCI) m/z [M+H] calcd 246.2, found 246.2.  
6-(cis-4-(tert-butyl)cyclohexyl)-2,3-dimethylpyridine (cis-13fx).  
As 4.4:1 mixture with trans-13fx. Pale yellow viscous liquid.  Rf = 
0.42 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.30 (d, 
J = 7.6 Hz, 1H), 7.04 (d, J = 7.6 Hz, 1H), 3.04 (bs, 1H), 2.47 (s, 
3H), 2.39-2.36 (m, 2H), 2.23 (s, 3H), 1.78-1.69 (m, 2H), 1.59-1.55 (m, 2H), 1.25-1.06 (m, 3H), 
0.80 (s, 9H).  13C NMR (100 MHz, CDCl3) δ 161.2, 156.0, 137.0, 127.5, 118.9, 48.2, 38.8, 33.6, 
32.6, 30.0, 27.5, 22.9, 18.7.  IR (NaCl, thin film) ν 2937, 2864, 1575, 1465, 1365 cm-1.  LRMS 
(ESI + APCI) m/z [M+H] calcd 246.2, found 246.2.  
5-(cis-4-(tert-butyl)cyclohexyl)-2,3-dimethylpyridine (cis-14fx).  
Pale yellow viscous liquid.  Rf = 0.12 (5:1 hexanes/EtOAc).  1H 
NMR (400 MHz, CDCl3) δ 8.32 (d, J = 1.6 Hz, 1H), 7.35 (d, J = 
0.8 Hz, 1H), 3.00 (bs, 1H), 2.46 (s, 3H), 2.27 (s, 3H), 2.22-2.19 (m, 














(s, 9H).  13C NMR (100 MHz, CDCl3) δ 153.6, 145.9, 137.6, 136.8, 130.5, 48.2, 34.2, 32.6, 30.4, 
27.5, 22.6, 19.3.  IR (NaCl, thin film) ν 2938, 2865, 1477, 1449, 1366, 1240 cm-1.  LRMS (ESI + 
APCI) m/z [M+H] calcd 246.2, found 246.2.  
Methyl 3,5,6-trimethylpicolinate (33fa).  White solid.  Rf = 0.18 
(3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.32 (s, 1H), 
3.96 (s, 3H), 2.52 (s, 6H), 2.30 (s, 3H).  13C NMR (100 MHz, 
CDCl3) δ 166.9, 154.7, 143.8, 141.1, 135.0, 133.3, 52.6, 22.4, 19.6, 19.2.  IR (NaCl, thin film) ν 
2947, 2925, 1704, 1598, 1552, 1445, 1382, 1316, 1241, 1186, 1154, 1065, 1041, 1022, 999, 910, 
832, 803, 713 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 180.1, found 180.1.  
Ethyl 3,5,6-trimethylpicolinate (33fb).  Pale yellow viscous 
liquid.  Rf = 0.23 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, 
CDCl3) δ 7.29 (s, 1H), 4.42 (q, J = 7.2 Hz, 2H), 2.50 (s, 3H), 2.47 
(s, 3H), 2.27 (s, 3H), 1.41 (t, J = 7.2 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 166.8, 154.7, 
144.7, 140.8, 134.6, 132.4, 61.5, 22.4, 19.5, 19.1, 14.4.  IR (NaCl, thin film) ν 2981, 1719, 1462, 
1310, 1237, 1155, 1062, 713 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 194.1, found 194.1. 
Dimethyl 5,6-dimethylpyridine-2,3-dicarboxylate (33fc).  
White solid.  Rf = 0.19 (3:1 hexanes/EtOAc).  1H NMR (400 
MHz, CDCl3) δ 7.88 (s, 1H), 3.96 (s, 3H), 3.89 (s, 3H), 2.57 (s, 
3H), 2.35 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 167.3, 166.1, 160.9, 148.2, 138.2, 133.7, 
123.7, 53.1, 52.8, 22.9, 19.1.  IR (NaCl, thin film) ν 2955, 1732, 1597, 1428, 1309, 1151, 1046, 
















Methyl 3-acetyl-5,6-dimethylpicolinate (33fd).  White solid. Rf 
= 0.11 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.54 
(s, 1H), 3.97 (s, 3H), 2.59 (s, 3H), 2.53 (s, 3H), 2.37 (s, 3H).  13C 
NMR (100 MHz, CDCl3) δ 200.5, 166.8, 159.7, 144.1, 136.2, 135.1, 134.8, 53.2, 29.7, 22.9, 
19.4.  IR (NaCl, thin film) ν 2954, 1744, 1692, 1591, 1552, 1429, 1365, 1301, 1261, 1161, 1137, 
1019 cm-1.  LRMS (ESI + APCI) m/z [M+H] calcd 208.1, found 208.1. 
Methyl 2-acetyl-5,6-dimethylnicotinate (34fd).  White solid. Rf 
= 0.34 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.71 
(s, 1H), 3.89 (s, 3H), 2.65 (s, 3H), 2.56 (s, 3H), 2.35 (s, 3H).  13C 
NMR (100 MHz, CDCl3) δ 201.0, 167.9, 159.4, 152.6, 137.6, 134.0, 124.4, 52.9, 27.5, 22.8, 
19.2.  IR (NaCl, thin film) ν 2955, 1733, 1595, 1432, 1356, 1301, 1272, 1161, 1131, 1022 cm-1.  
LRMS (ESI + APCI) m/z [M+H] calcd 208.1, found 208.1.  
2-Butyl-3-propyl-5,6-dihydrobenzo[h]quinoline (33kh).  
Colorless viscous liquid.  Rf = 0.14 (3:1 hexanes/DCM).  1H NMR 
(400 MHz, CDCl3) δ 8.34 (d, J = 7.6 Hz, 1H), 7.36-7.19 (m, 4H), 
2.94-2.81 (m, 6H), 2.60 (t, J = 7.6 Hz, 2H), 1.80 (m, 2H), 1.64 (m, 2H), 1.47 (m, 2H), 1.01 (t, J = 
5.7, 3H), 0.99 (t, J = 5.4, 3H).  13C NMR (100 MHz, CDCl3) δ 158.2, 149.3, 137.9, 136.3, 135.2, 
134.0, 128.8, 128.4, 127.7, 127.1, 124.8, 34.4, 34.2, 31.7, 28.5, 27.8, 24.0, 23.0, 14.3.  IR (NaCl, 
thin film) ν 2957, 2931, 2870, 1553, 1461, 1438, 1377, 915, 740 cm-1.  LRMS (ESI + APCI) m/z 
















A.1.5 Mechanistic Experiments 
Isotope experiments were conducted with AcOD (purchased from Sigma-Aldrich Co. and 
used as received) according to the reaction procedure described above for the length of time 
indicated.  Deuterium incorporation was determined by integration of the 1H NMR spectra 
collected with first relaxation delay (d1) = 15 seconds of the crude reaction mixtures. 
 A stoichiometric experiment was performed according to the following procedure.  A 0.5 
dram vial was charged with RhCp*(OAc)2 (9.6 mg, 100 mol %)9 and a solution of 24f (0.027 
mmol) and 15a (2.7 mg, 1 equiv) in 0.09 mL 2:1 DCE/AcOH was added.  The vial was flushed 
with argon, sealed and heated at 85 °C in an aluminum heating block for 20 minutes.  The 
solvent was removed and the reaction mixture was analyzed by 1H NMR (300 MHz, CDCl3).  


































[RhCp*Cl2]2 (2.5 mol %)
AgOAc (2.1 equiv)
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A.2.1 General Methods 
All reactions were carried out in oven–dried glassware under an atmosphere of argon 
with magnetic stirring.  Reagent grade silver acetate and silver tosylate and ACS grade acetic 
acid were purchased from Sigma–Aldrich Co. and used without further purification. ACS grade 
potassium persulfate was purchased from Mallinckrodt Chemicals and used as received.  
1,1,1,3,3,3–Hexafluoro–2–propanol was distilled from 3Å molecular sieves and dichloroethane 
was distilled from calcium hydride under an atmosphere of argon.  2–Pentenoic acid (14b) and 
cinnamic acid (14e) were purchased from Sigma–Aldrich Co. and Alfa Aesar, respectively, and 
used without further purification.  Crotonic acid (14a) and acrylic acid (16) were distilled under 
reduced pressure prior to use.  Methoxycinnamic acids 14f and 14i were recrystallized from 
methanol prior to use.  Alkyl acrylic acids1 14c, 14d, 14j–n, and 14v, (hetero)aryl acrylic acids2 
14g, 14h, and 14o–t, and substrate 14u3 were synthesized according to literature procedure.  
[RhCp*Cl2]2,4 RhCp*(OAc)25 and [RhCpCF3Cl2]26 were prepared as previously reported.  
Column chromatography was performed on Silicycle® SilicaFlash® P60 (230–400 mesh).  Thin 
layer chromatography was performed on Silicycle® 250µm silica gel 60A plates.  Visualization 
was accomplished with UV light (254 nm) or potassium permanganate. 
1H NMR and 13C NMR spectra were collected at ambient temperature in CDCl3 or 
CD2Cl2 on a Varian 400 MHz.  Chemical shifts are expressed as parts per million (δ, ppm) and 
are referenced to 7.26 (CHCl3) or 5.29 (CH2Cl2) for 1H NMR and 77.0 (CDCl3) or 53.5 (CD2Cl2) 
for 13C NMR.  Signal data uses the following abbreviations: s = singlet, d = doublet, t = triplet, q 
= quartet, m = multiplet and J = coupling constant.  Mass spectra were obtained on an Agilent 
Technologies 6130 Quadropole Mass Spec (LRMS).  Infrared spectra were collected on a Bruker 
Tensor 27 FT–IR spectrometer or a Nicolet SX–60 FT–IR spectrometer.  
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A.2.2 General Procedure for Oxime Ester Synthesis 
O–Pivaloyl oxime esters 11 were generated from the corresponding α,β–unsaturated 
ketones according to the following representative procedure, adapted from the literature.7  
Hydroxylamine hydrochloride (347 mg, 7 mmol, 1.4 equiv) and Na2CO3 (742 mg, 7 mmol, 1.4 
equiv) were added to the enone (5 mmol) in 15 mL MeOH and the mixture was stirred at 65 °C 
for 1 hour (or room temperature for 3 hours in the case of 11c).  The solvent was removed in 
vacuo and the resulting residue was dissolved in 10 mL CH2Cl2 and cooled to 0 °C.  After the 
addition of Et3N (1.74 mL, 12.5 mmol, 2.5 equiv), a solution of pivaloyl chloride (1.23 mL, 10 
mmol, 2 equiv) in 5 mL CH2Cl2 was added dropwise at 0 °C.  The mixture was stirred at room 
temperature overnight and quenched with water.  The aqueous layer was extracted with CH2Cl2 
three times and the combined organic layers were washed with saturated NaHCO3 and brine, 
dried over MgSO4, filtered and concentrated in vacuo.  The crude product was purified by flash 
column chromatography. 
Compounds 11a–c and 11e were characterized in our previous report.8 
(E)–2–methylenecycloheptanone O–pivaloyl oxime (11d).  Colorless liquid.  
Rf = 0.15 (10:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 5.48 (d, J = 
1.6 Hz, 1H), 5.06 (d, J = 1.6 Hz, 1H), 2.64 (m, 2H), 2.38 (m, 2H), 1.64 (m, 6H), 1.28 (s, 9H).  
13C NMR (100 MHz, CDCl3) δ 175.0, 170.9, 144.3, 117.2, 38.8, 34.9, 30.6, 29.4, 28.9, 27.3, 
25.3.  IR (NaCl, thin film) ν 2928, 1755, 1479, 1270, 1099, 1026, 882 cm–1.  LRMS (ESI) m/z 




A.2.3 General Procedure for Pyridine Synthesis 
A 0.5 dram vial was charged with oxime ester 11 (0.21 mmol), AgOTs (52.7 mg, 0.189 
mmol, 0.9 equiv) and K2S2O8 (59.6 mg, 0.221 mmol, 1.05 equiv) and a solution of [RhCpCF3Cl2]2 
(3.8 mg, 0.005 mmol, 0.025 equiv) and alkene 14 (0.252 mmol, 1.2 equiv) in 0.7 mL HFIP was 
added.  The vial was flushed with argon, sealed and heated at 58 °C in an aluminum heating 
block for 12 hours.  In the event that an observable amount of 11 remained after 12 hours, the 
mixture was heated at 100 °C until it was consumed.  The mixture was diluted with CH2Cl2 and 
washed with 1M aqueous NaOH.  The aqueous layer was extracted twice with CH2Cl2 and the 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo.  The 
residue was dissolved in EtOAc and passed through a short plug of silica to provide analytically 
pure product.   
Compounds 15bj and 15bm were characterized in our previous report.8  Compounds 
15bd and 15be were characterized by Ellman and coworkers.9  Compound 17c was characterized 
by Craig and coworkers.10 
2–Butyl–5–hexyl–3–propylpyridine (15aj).  Yellow viscous liquid.  Rf = 
0.61 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 2.0 
Hz, 1H), 7.21 (d, J = 1.6 Hz, 1H), 2.74 (m, 2H), 2.54 (m, 4H), 1.69–1.53 (m, 
6H), 1.41 (m, 2H), 1.34–1.25 (m, 6H), 0.96 (m, 6H), 0.87 (t, J = 6.4 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ 157.4, 146.4, 136.9, 135.1, 134.7, 34.2, 34.2, 32.6, 32.0, 31.6, 
31.2, 28.9, 23.9, 22.9, 22.6, 14.0, 14.0.  IR (NaCl, thin film) ν 2959, 1562, 1459, 1378, 1287, 






5–hexyl–2–methyl–3–phenylpyridine (15cj).  Yellow orange viscous 
liquid.  Rf = 0.42 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.32 
(d, J = 2.0 Hz, 1H), 7.45–7.31 (m, 6H), 2.61 (t, J = 7.6 Hz, 2H), 2.47 (s, 3H), 
1.62 (m, 2H), 1.37–1.26 (m, 6H), 0.88 (t, J = 6.8 Hz, 3H).  13C NMR (100 
MHz, CDCl3) δ 152.9, 147.8, 140.1, 137.3, 136.5, 135.3, 129.0, 128.3, 127.3, 32.5, 31.6, 31.4, 
28.8, 22.8, 22.5, 14.0.  IR (NaCl, thin film) ν 2928, 2857, 1459, 1183, 1027, 909, 702 cm–1.  
LRMS (ESI + APCI) m/z [M+H] calcd 254.2, found 254.7. 
3–Hexyl–6,7,8,9–tetrahydro–5H–cyclohepta[b]pyridine (15dj).  Yellow 
viscous liquid.  Rf = 0.38 (3:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) 
δ 8.08 (d, J = 1.6 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 2.99 (m, 2H), 2.73 (m, 
2H), 2.52 (t, J = 7.6 Hz, 2H), 1.85 (m, 2H), 1.70–1.54 (m, 6H), 1.34–1.25 
(m, 6H), 0.87 (t, J = 6.4 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 160.3, 145.5, 137.7, 136.8, 
135.4, 38.7, 35.3, 32.5, 31.6, 31.1, 28.9, 28.0, 26.5, 22.6, 14.0.  IR (NaCl, thin film) ν 2926, 
2855, 1468, 1287, 1182, 958 cm–1.  LRMS (ESI + APCI) m/z [M+H] calcd 232.2, found 232.7. 
 5–(4–Methoxyphenyl)–2,3–dimethylpyridine (15bf).  Yellow orange 
viscous liquid.  Rf = 0.34 (1:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) 
δ 8.51 (s, 1H), 7.56 (s, 1H), 7.49 (d, J = 8.0 Hz, 2H), 6.99 (d, J = 8.4 Hz, 
2H), 3.85 (s, 3H), 2.53 (s, 3H), 2.33 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 
159.4, 155.2, 144.3, 135.3, 134.0, 131.2, 130.4, 128.0, 114.4, 55.3, 22.1, 
19.2.  IR (NaCl, thin film) ν 2936, 1610, 1516, 1470, 1387, 1287, 1249, 1180, 1112, 1033, 830 












 5–(Furan–2–yl)–2,3–dimethylpyridine (15bh).  Yellow orange viscous 
liquid.  Rf = 0.48 (1:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.64 
(d, J = 2.0 Hz, 1H), 7.71 (d, J = 1.2 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 6.68 
(d, J = 3.2 Hz, 1H), 6.48 (dd, J = 3.2 Hz, 1.6 Hz, 1H), 2.53 (s, 3H), 2.33 (s, 
3H).  13C NMR (100 MHz, CDCl3) δ 155.4, 151.1, 142.6, 141.3, 132.6, 131.7, 125.0, 111.7, 
105.8, 21.9, 19.1.  IR (NaCl, thin film) ν 2922, 1684, 1596, 1401, 1143, 1017, 885, 735 cm–1.  
LRMS (ESI + APCI) m/z [M+H] calcd 174.1, found 174.5. 
5–(3–Methoxyphenyl)–2,3–dimethylpyridine (15bi).  Yellow viscous 
liquid.  Rf = 0.37 (1:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.55 
(d, J = 2.0 Hz, 1H), 7.59 (d, J = 2.0 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.14 (d, 
J = 7.6 Hz, 1H), 7.08 (t, J = 2.4 Hz, 1H), 6.91 (dd, J = 8.0 Hz, 2.4 Hz, 1H), 
3.86 (s, 3H), 2.54 (s, 3H), 2.34 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 160.0, 154.0, 144.6, 
139.4, 135.7, 134.1, 131.3, 130.0, 119.4, 113.0, 112.7, 55.3, 22.2, 19.2.  IR (NaCl, thin film) ν 
2941, 1583, 1471, 1387, 1285, 1219, 1046, 870, 827, 781, 730, 697 cm–1.  LRMS (ESI + APCI) 
m/z [M+H] calcd 214.1, found 214.6. 
5–Isobutyl–2,3–dimethylpyridine (15bk).  Pale yellow viscous liquid.  Rf = 
0.33 (1:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 1.6 
Hz, 1H), 7.19 (d, J = 1.2 Hz, 1H), 2.46 (s, 3H), 2.40 (d, J = 7.2 Hz, 2H), 2.25 
(s, 3H), 1.82 (m, 1H), 0.89 (d, J = 6.8 Hz).  13C NMR (100 MHz, CDCl3) δ 
154.2, 146.7, 138.0, 134.2, 130.8, 41.8, 30.0, 22.2, 21.9, 19.1.  IR (NaCl, thin film) ν 2957, 














5–(3–Chloropropyl)–2,3–dimethylpyridine (15bl).  Pale yellow viscous 
liquid.  Rf = 0.25 (1:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.16 
(s, 1H), 7.24 (s, 1H), 3.51 (t, J = 6.4 Hz, 2H), 2.71 (t, J = 7.2 Hz, 2H), 2.46 
(s, 3H), 2.25 (s, 3H), 2.05 (m, 2H).  13C NMR (100 MHz, CDCl3) δ 154.8, 
146.1, 137.5, 133.3, 131.2, 43.9, 33.7, 29.3, 22.0, 19.1.  IR (NaCl, thin film) ν 2922, 1476, 1444, 
1413, 1286, 1213, 1182, 731, 706 cm–1.  LRMS (ESI + APCI) m/z [M+H] calcd 184.1, found 
184.5. 
5–Cyclopropyl–2,3–dimethylpyridine (15bn).  Pale yellow viscous liquid.  
Rf = 0.34 (1:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 
7.04 (s, 1H), 2.44 (s, 3H), 2.22 (s, 3H), 1.82 (m, 1H), 0.96 (m, 2H), 0.65 (m, 
2H).  13C NMR (100 MHz, CDCl3) δ 153.7, 144.3, 136.8, 134.4, 131.1, 21.6, 
19.1, 12.5, 8.6.  IR (NaCl, thin film) ν 2922, 1480, 1460, 1286, 1224, 1183, 1101, 1020, 989, 
729 cm–1.  LRMS (ESI + APCI) m/z [M+H] calcd 148.1, found 148.4. 
5–(2–Methoxyphenyl)–2,3–dimethylpyridine (15br).  Yellow viscous 
liquid.  Rf = 0.37 (1:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.48 
(d, J = 1.6 Hz, 1H), 7.58 (d, J = 1.2 Hz, 1H), 7.36–7.28 (m, 2H), 7.04 (t, J = 
7.6 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 3.81 (s, 3H), 2.54 (s, 3H), 2.32 (s, 3H).  
13C NMR (100 MHz, CDCl3) δ 156.6, 155.3, 146.7, 138.0, 131.8, 130.5, 129.1, 127.2, 120.9, 
111.2, 55.5, 22.2, 19.2.  IR (NaCl, thin film) ν 2941, 1598, 1498, 1471, 1392, 1242, 1122, 1026, 












2,3–Dimethyl–5–(thiophen–2–yl)pyridine (15bt).  Yellow orange viscous 
liquid.  Rf = 0.51 (1:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 8.59 
(d, J = 2.0 Hz, 1H), 7.62 (d, J = 1.2 Hz, 1H), 7.31 (m, 2H), 7.10 (m, 1H), 
2.52 (s, 3H), 2.33 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 155.8, 143.0, 
140.5, 134.7, 131.7, 128.3, 128.1, 125.4, 123.7, 21.9, 19.1.  IR (NaCl, thin film) ν 2920, 1474, 
1402, 1231, 895, 843, 697 cm–1.  LRMS (ESI + APCI) m/z [M+H] calcd 190.1, found 190.1.   
 
A.2.4 Preparation of Picolinic Acid 20aa 
An oven–dried 20 mL vial was charged with [RhCp*Cl2]2 (27.8 mg, 0.025 equiv) and 
AgOAc (631 mg, 2.1 equiv) and a solution of oxime substrate 11a (456 mg, 1.8 mmol) and ethyl 
acrylate 22 (0.27 mL, 1.2 equiv) in 0.7 mL 2:1 DCE/AcOH was added.  The vial was flushed 
with argon, sealed and heated at 85 °C in a sand bath for 14 hours.  The solids were filtered and 
the mixture was diluted with DCM and washed with 15% Na2CO3.  The aqueous layer was 
extracted twice with DCM and the combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo.  The crude product was purified by flash column chromatography (5:1 
hexanes/EtOAc) to afford 23 (168 mg, 35% yield). 
Ethyl 6–butyl–3–methyl–5–propylpicolinate (23).  Colorless liquid.  Rf = 
0.35 (5:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.27 (s, 1H), 4.42 
(q, J = 7.2 Hz, 2H), 2.79 (m, 2H), 2.58 (m, 2H), 2.45 (s, 3H), 1.69–1.55 (m, 
4H), 1.46–1.36 (m, 5H), 0.95 (m, 6H).  13C NMR (100 MHz, CDCl3) δ 167.0, 157.9, 145.2, 











2960, 2873, 1719, 1456, 1366, 1309, 1244, 1150, 1058 cm–1.  LRMS (ESI + APCI) m/z [M+H] 
calcd 264.2, found 264.7. 
A solution of pyridine 23 (146 mg, 0.55 mmol) in 7.4 mL EtOH was added to LiOH (106 
mg, 8 equiv) in 3.7 mL H2O and the mixture was stirred at room temperature overnight.  The 
solution was acidified with 3M HCl and extracted with EtOAc.  The organic layer was washed 
with H2O and brine, dried over MgSO4, filtered and concentrated in vacuo to provide 20aa (107 
mg, 83% yield).  
6–Butyl–3–methyl–5–propylpicolinic acid (20aa).  Colorless liquid.  Rf = 
0.24 (1:1 hexanes/EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.40 (s, 1H), 2.78 
(m, 2H), 2.68 (s, 3H), 2.63 (m, 2H), 1.74–1.59 (m, 4H), 1.41 (m, 2H), 0.98 
(m, 6H).  13C NMR (100 MHz, CDCl3) δ 164.7, 156.3, 142.0, 140.8, 139.8, 134.3, 33.8, 33.2, 
30.9, 23.4, 22.6, 19.4, 14.0, 14.0.  IR (NaCl, thin film) ν 3420, 2960, 2873, 1763, 1639, 1460, 
1363 cm–1.  LRMS (ESI + APCI) m/z [M+H] calcd 236.2, found 236.7. 
 
A.2.5 Deuterium Incorporation Study 
An isotope experiment was performed according to the procedure described above with 
11b and 14a in 2,2,2–trifluoroethanol–d1 (purchased from Sigma–Aldrich Co. and used as 
received) as the solvent for one hour.  Deuterium incorporation was determined by integration of 









A.2.6 Preparation and Reactions of Rhodium Complexes 29 and 30 
A 0.5 dram vial was charged with RhCp*(OAc)211 (0.054 mmol, 100 mol %) and a 
solution of oxime ester 11b (0.054 mmol) and crotonic acid 14a (0.054 mmol, 1 equiv) in 0.18 
mL HFIP was added.  The vial was flushed with argon, sealed and heated at 58 °C in an 
aluminum heating block for 30 minutes.  The mixture was transferred to a 1 dram vial, the 
solvents were removed and a solution of TMSCl (0.054 mmol, 1 equiv) in 1 mL Et2O was added.  
After 10 minutes stirring at room temperature, the heterogeneous mixture was filtered and the 
solid rinsed with Et2O.  The solid was dissolved in DCM, the solution was filtered and the filtrate 
was concentrated to give 29 (16.2 mg, 68% yield) as an orange solid.  A 0.5 dram vial was 
charged with a solution of complex 29 (7.5 mg, 0.017 mmol) in 0.06 mL HFIP, flushed with 
argon and heated for 24 hours in an aluminum heating block.  The solvent was removed and the 
reaction mixture analyzed by 1H NMR. 
Slow evaporation of a concentrated solution of 29 in DCM afforded prismatic orange 
crystals suitable for X–ray diffraction analysis.   
Rhodium chloride complex 29. 1H NMR (400 MHz, CDCl3) δ 5.88 (bs, 
1H), 3.59 (dq, J = 16.0 Hz, 2.4 Hz, 1H), 2.71–2.61 (m, 1H), 2.52 (d, J = 2.4 















[RhCpCF3Cl2]2 (2.5 mol %)
AgOTs (0.9 equiv)
K2S2O8 (1.05 equiv)













Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 176.8, 172.0, 141.7, 127.4, 93.5 (d, J = 8.6 Hz), 70.3, 
31.5, 26.9, 21.3, 19.3, 9.1.  IR (thin film) ν 2922, 1639, 1587, 1448, 1323, 1089, 1025, 921, 809, 
726 cm–1.  LRMS (ESI + APCI) m/z [M–Cl] calcd 404.1, found 404.3. 
A 1 dram vial was charged with 29 (29.7 mg, 0.068 mmol) and AgOAc (0.068, 1 equiv) 
and 1.4 mL DCM was added.  The vial was flushed with argon, sealed, wrapped in aluminum 
foil and stirred at room temperature overnight.  The heterogeneous mixture was filtered and the 
filtrate concentrated to give 30 (25.0 mg, 80% yield) as an orange solid.  A 0.5 dram vial was 
charged with a solution of complex 30 (12.7 mg, 0.027 mmol) in 0.09 mL HFIP, flushed with 
argon and heated for 24 hours in an aluminum heating block.  The solvent was removed and the 
reaction mixture analyzed by 1H NMR.  Alternately, a 0.5 dram vial was charged with AgOTs 
(0.029 mmol, 1 equiv) and a solution of 30 (13.4 mg, 0.029 mmol) in 0.1 mL HFIP was added.  
The vial was flushed with argon, sealed and heated at 58 °C in an aluminum heating block for 24 
hours.  The solvent was removed and the reaction mixture analyzed by 1H NMR. 
Rhodium acetate complex 30. 1H NMR (400 MHz, CD2Cl2) δ 5.84 (bs, 
1H), 3.40 (dq, J = 15.6 Hz, 2.4 Hz, 1H), 2.55–2.43 (m, 1H), 2.49 (d, J = 
2.8 Hz, 3H), 1.87 (dd, J = 2.4 Hz, 1.6 Hz, 3H), 1.83 (s, 3H), 1.57 (s, 
15H), 1.27 (d, J = 6.8 Hz, 3H).  13C NMR (100 MHz, CD2Cl2) δ 176.8, 176.6, 171.4, 141.2, 
127.8, 92.8 (d, J = 8.8 Hz), 70.1, 31.6, 26.5, 24.3, 21.1, 19.1, 9.0.  IR (thin film) ν 2922, 1640, 
1613, 1448, 1359, 1315, 1160, 1090, 1026, 809, 727, 666 cm–1.  LRMS (ESI + APCI) m/z [M–







































































































































































A.2.8 Crystallographic Data for Rhodium Complex 29 
Prismatic orange crystals were obtained after slow evaporation of a concentrated solution 
of 29 in DCM in loosely sealed vial.  A single crystal was coated in Paratone–N oil and mounted 
under a stream of nitrogen.  X–ray diffraction data was collected on a Bruker Kappa Apex II 
CCD diffractometer with Mo Kα radiation (λ = 0.71073 Å) and a graphite monochromator.  Data 
integration and Lorentz and polarization corrections were accomplished with Bruker APEX2 
software and semiempirical absorption corrections were applied using SCALE with the aid of 
numerical face indexing.12  The crystal structure was solved with SHELXTL software.13 The 
thermal parameters of all non–hydrogen atoms were refined anisotropically and hydrogen atoms 
were added in idealized positions. 
Table 1.  Crystal data and structure refinement for 29. 
Identification code  rovis178 
Empirical formula  C19H27NO2RhCl 
Formula weight  439.78 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 10.0060(6) Å α= 90°. 
 b = 12.4200(6) Å β= 106.763(3)°. 
 c = 15.5420(12) Å γ = 90°. 
Volume 1849.4(2) Å3 
Z 4 
Density (calculated) 1.579 Mg/m3 
Absorption coefficient 1.079 mm–1 
F(000) 904 
Crystal size 0.35 x 0.13 x 0.11 mm3 
Theta range for data collection 2.14 to 26.41°. 
Index ranges –12<=h<=12, –15<=k<=15, –19<=l<=19 
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Reflections collected 60907 
Independent reflections 3791 [R(int) = 0.0479] 
Completeness to theta = 26.41° 99.9 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.8887 and 0.7039 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 3791 / 0 / 225 
Goodness–of–fit on F2 1.056 
Final R indices [I>2sigma(I)] R1 = 0.0201, wR2 = 0.0439 
R indices (all data) R1 = 0.0282, wR2 = 0.0477 
Largest diff. peak and hole 0.441 and –0.325 e.Å–3 
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 29.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Rh(1) 5817(1) 2969(1) 2469(1) 12(1) 
C(1) 8845(2) 3809(2) 3093(1) 15(1) 
C(2) 10154(2) 4189(2) 2928(1) 18(1) 
C(3) 10348(2) 4010(2) 2130(2) 20(1) 
C(4) 9311(2) 3467(2) 1366(1) 19(1) 
C(5) 7866(2) 3434(2) 1514(1) 16(1) 
C(6) 8750(2) 3865(2) 4034(1) 22(1) 
C(7) 11201(2) 4768(2) 3674(2) 25(1) 
C(8) 9231(2) 4020(2) 478(2) 27(1) 
C(9) 6980(2) 2484(2) 1021(1) 19(1) 
N(1) 7809(2) 3456(1) 2452(1) 14(1) 
O(1) 7174(2) 2132(1) 329(1) 30(1) 
O(2) 6066(1) 2111(1) 1378(1) 19(1) 
C(10) 3796(2) 2905(2) 2710(1) 16(1) 
C(11) 3635(2) 3255(2) 1814(1) 17(1) 
C(12) 4431(2) 4230(2) 1847(1) 17(1) 
C(13) 5038(2) 4501(2) 2778(1) 18(1) 
C(14) 4677(2) 3680(2) 3312(1) 16(1) 
C(15) 3146(2) 1944(2) 3008(2) 23(1) 
C(16) 2850(2) 2698(2) 969(1) 24(1) 
C(17) 4479(2) 4901(2) 1056(2) 28(1) 
C(18) 5867(2) 5496(2) 3098(2) 27(1) 
C(19) 5035(2) 3620(2) 4316(1) 23(1) 









Table 3.   Bond lengths [Å] and angles [°] for 29. 
___________________________________________  
Rh(1)–O(2)  2.0779(14) 
Rh(1)–N(1)  2.0904(16) 
Rh(1)–C(12)  2.1299(19) 
Rh(1)–C(11)  2.1556(19) 
Rh(1)–C(14)  2.1592(19) 
Rh(1)–C(13)  2.162(2) 
Rh(1)–C(10)  2.1618(19) 
Rh(1)–Cl(1)  2.4089(5) 
C(1)–N(1)  1.290(3) 
C(1)–C(2)  1.483(3) 
C(1)–C(6)  1.495(3) 
C(2)–C(3)  1.328(3) 
C(2)–C(7)  1.501(3) 
C(3)–C(4)  1.493(3) 
C(4)–C(8)  1.523(3) 
C(4)–C(5)  1.529(3) 
C(5)–N(1)  1.475(2) 
C(5)–C(9)  1.540(3) 
C(9)–O(1)  1.228(2) 
C(9)–O(2)  1.285(2) 
C(10)–C(11)  1.424(3) 
C(10)–C(14)  1.450(3) 
C(10)–C(15)  1.495(3) 
C(11)–C(12)  1.442(3) 
C(11)–C(16)  1.491(3) 
C(12)–C(13)  1.439(3) 
C(12)–C(17)  1.498(3) 
C(13)–C(14)  1.426(3) 
C(13)–C(18)  1.493(3) 



















































































Symmetry transformations used to generate equivalent atoms:  
 
 
Table 4.   Anisotropic displacement parameters  (Å2x 103) for 29.  The anisotropic 
displacement factor exponent takes the form:  –2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Rh(1) 10(1)  15(1) 11(1)  0(1) 3(1)  1(1) 
C(1) 14(1)  15(1) 17(1)  3(1) 4(1)  2(1) 
C(2) 13(1)  16(1) 24(1)  7(1) 4(1)  2(1) 
C(3) 14(1)  18(1) 28(1)  7(1) 10(1)  2(1) 
C(4) 20(1)  18(1) 23(1)  3(1) 12(1)  3(1) 
C(5) 16(1)  19(1) 16(1)  1(1) 7(1)  4(1) 
C(6) 18(1)  31(1) 17(1)  –2(1) 5(1)  –5(1) 
C(7) 16(1)  29(1) 29(1)  4(1) 3(1)  –5(1) 
C(8) 31(1)  31(1) 26(1)  6(1) 20(1)  7(1) 
C(9) 16(1)  24(1) 16(1)  –1(1) 3(1)  7(1) 
N(1) 13(1)  15(1) 13(1)  1(1) 6(1)  2(1) 
O(1) 30(1)  44(1) 20(1)  –13(1) 12(1)  –3(1) 
O(2) 16(1)  23(1) 18(1)  –7(1) 6(1)  0(1) 
C(10) 10(1)  21(1) 18(1)  –1(1) 6(1)  3(1) 
C(11) 10(1)  23(1) 16(1)  –1(1) 3(1)  6(1) 
C(12) 13(1)  20(1) 18(1)  3(1) 6(1)  6(1) 
C(13) 14(1)  17(1) 22(1)  –2(1) 6(1)  5(1) 
C(14) 14(1)  20(1) 17(1)  –3(1) 6(1)  3(1) 
C(15) 20(1)  26(1) 26(1)  –1(1) 10(1)  –2(1) 
C(16) 18(1)  35(1) 17(1)  –3(1) 1(1)  4(1) 
C(17) 26(1)  33(1) 27(1)  13(1) 10(1)  9(1) 
C(18) 27(1)  16(1) 38(1)  –4(1) 9(1)  1(1) 
C(19) 22(1)  34(1) 14(1)  –3(1) 6(1)  4(1) 
Cl(1) 20(1)  19(1) 24(1)  6(1) 6(1)  3(1) 
______________________________________________________________________________ 
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Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 29. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(3) 11202 4242 2040 24 
H(4) 9628 2709 1332 23 
H(5) 7376 4100 1226 19 
H(6A) 8771 4620 4222 33 
H(6B) 9541 3480 4436 33 
H(6C) 7875 3532 4062 33 
H(7A) 12021 4952 3479 38 
H(7B) 11484 4301 4204 38 
H(7C) 10781 5428 3825 38 
H(8A) 8949 4772 503 40 
H(8B) 8543 3649 –11 40 
H(8C) 10147 3993 369 40 
H(15A) 2657 1515 2482 35 
H(15B) 2481 2181 3324 35 
H(15C) 3875 1504 3412 35 
H(16A) 3503 2297 726 36 
H(16B) 2354 3232 528 36 
H(16C) 2175 2197 1098 36 
H(17A) 3694 5407 910 42 
H(17B) 4418 4433 539 42 
H(17C) 5359 5304 1202 42 
H(18A) 5245 6123 2979 41 
H(18B) 6577 5580 2781 41 
H(18C) 6324 5440 3746 41 
H(19A) 5751 4158 4583 35 
H(19B) 5391 2900 4518 35 
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